2021 Accepted Abstracts
Disease Modifying Therapies
Disease Management
Neuroimaging
Psychosocial
Rehabilitation
Disease Modifying Therapies
- DMT01
Design of the Phase II, Double-Blind, Placebo-Controlled Dose-Expansion Portion of a Two-Part, Phase I/II, Multicenter Trial in Progressive Multiple Sclerosis
Amit Bar-Or, MD1, Laurence Gamelin, MD, PhD2, Wei Ye, PhD2, Jonathan Willmer, MD2, Blake T Aftab, PhD2 and Michael P Pender, MD, PhD3, (1)Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (2)Atara Biotherapuetics, South San Francisco, CA, (3)The University of Queensland, Brisbane, Australia - DMT02
Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease-Modifying Drugs: A Systematic Review
Kerstin Hellwig, MD, PhD1, Elisabetta Verdun di Cantogno, MD, PhD2 and Meritxell Sabidó, MD, PhD2, (1)St. Joseph and St. Elisabeth Hospital, Ruhr University, Bochum, Germany, (2)Merck KGaA, Darmstadt, Germany - DMT03
Improvements in Work Productivity and Activity Impairment in Ocrelizumab-Treated Patients with RRMS: 2-Year Data from the CASTING Study
Giancalo Comi, PhD1, Gary Cutter, PhD2, Ilya Kister, MD3, Bart van Wijmeersch, MD, PhD4, Regine Buffels, MD5, Thomas Kuenzel, PhD5, Yekaterina Poloz, PhD6 and Patrick Vermersch, PhD7, (1)Vita-Salute San Raffaele University, Milan, Italy, (2)University of Alabama at Birmingham, Birmingham, AL, (3)New York University Langone Medical Center, Multiple Sclerosis Comprehensive Care Center, New York, NY, (4)University MS Centre, Pelt, Hasselt University, Hasselt, Belgium, (5)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (6)F. Hoffman-La Roche Ltd, Mississauga, ON, Canada, (7)University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Imminent, Lille, France - DMT04
Efficacy and Safety of Ublituximab Versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 Ultimate I and II Trials
Lawrence Steinman, MD1, Edward J. Fox, MD, PhD2, Hans-Peter Hartung, M.D.3, Enrique Alvarez, MD, PhD4, Peiqing Qian, MD5, Sibyl Wray, MD6, Derrick Robertson, MD7, DeRun Huang, MD, PhD8, Krysztof Selmaj, MD, PhD9, Daniel Wynn, MD10, Michael S Weiss, J.D.11, Jenna Bosco, BA11, Sean Power, BA11, Koby Mok, PhD11 and Bruce A.C. Cree, MD, PhD, MAS12, (1)Stanford University School of Medicine, Stanford, CA, (2)Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock, TX, (3)Department of Neurology, Medical Faculty, Heinrich Heine University, Dusseldorf, Germany, (4)University of Colorado School of Medicine, Aurora, CO, (5)Swedish Neuroscience Institute, Seattle, WA, (6)Hope Neurology, Knoxville, TN, (7)University of South Florida, Morsani College of Medicine, Tampa, FL, (8)MDH Research, Westerville, OH, (9)Medical Academy of Lodz, Lodz, Poland, (10)Consultants in Neurology MS Center, Northbrook, IL, (11)TG Therapeutics, New York, NY, (12)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA - DMT05
Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design
Matthew Craner, MB ChB FRCP PhD1, Riley Bove, MD2, Dawn Langdon, PhD3, Daniel Detka, PhD4, Javier Ricart, PhD5, Alomi Mistry, MS6, Patricia Maxwell, BS7, Chaitali Babanra Pisal, MS6, Pruthvi Desireddy, MD6, Dee Stoneman, MPharm4, Marina Ziehn, PhD4 and Tobias Derfuss, MD8, (1)John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, (2)University of California San Francisco, San Francisco, CA, (3)Royal Holloway, University of London, London, United Kingdom, (4)Novartis Pharma AG, Basel, Switzerland, (5)Novartis Farmacéutica, Barcelona, Spain, (6)Novartis Healthcare Pvt. Ltd., Hyderabad, India, (7)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (8)Neurology Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine and Biomedicine, University Hospital and University of Basel, Basel, Switzerland - DMT06
COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy
Matthew A Tremblay, MD, Ph.D1, Andrew Sylvester, MD1, Mary Yarussi, BSN1, Phoebe Del Boccio, PhD1, Meera Patel, BS1, J Tamar Kalina, PhD2, Jason P. Mendoza, PhD2 and Robin Avila, PhD2, (1)Multiple Sclerosis Comprehensive Care Center, RWJ Barnabas Health, Livingston, NJ, (2)Biogen, Cambridge, MA - DMT07
Recently Diagnosed Early-Stage RRMS: Neda, ARR, Disability Progression, Serum Neurofilament and Safety: 1-Year Interim Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Timothy Vollmer, MD1, Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC2, Joep Killestein, MD, PhD3, Carlos Nos, MD4, Ludo Vanopdenbosch, MD5, Regine Buffels, MD6, Karen Kadner, MD, PhD6, Thomas Kuenzel, PhD6, Hans-Peter Hartung, M.D.7 and on behalf of the ENSEMBLE Investigators and Steering Committee, (1)Department of Neurology, University of Colorado School of Medicine, Aurora, CO, (2)University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (3)Department of Neurology, VU University Medical Center, Amsterdam, Netherlands, (4)Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, 08035, Barcelona, Spain, (5)Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, (6)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (7)Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine-University Düsseldorf, Dusseldorf, Germany
Disease Management
- DXM01
Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire
Tjalf Ziemssen, MD, PhD1, Enrique Alvarez, MD, PhD2, Virender Bhan, MD3, Jason Burton, MBBS4, Olaf Hoffmann, PD Dr. med.5, Celia Oreja-Guevara, MD6, René Robles-Cedeño, MD, PhD7, Maria Trojano, MD8, Patrick Vermersch, MD, PhD9, Salvatore Napoli, MD10, Augusto Miravalle, MD11, Yan Xu, MD, PhD12, Jo Vandercappellen, PhD, MBA13, Mudeer Khwaja, BSc13, Mark Marchaterre, IT BS14, Bianca Stadler, PhD15, Thomas Hach, MD13 and Gavin Giovannoni, MD, PhD16, (1)Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany, (2)University of Colorado School of Medicine, Aurora, CO, (3)University of British Columbia, Vancouver, BC, Canada, (4)Centre for Neuromuscular and Neurological Disorders, Western Australian Neuroscience Research Institute, The University of Western Australia, Perth, Australia, (5)Department of Neurology, Alexianer St. Josefs Hospital, Potsdam, Germany, (6)Department of Neurology, University Hospital San Carlos, Idissc, Madrid, Spain, (7)Neuroimmonology and Multiple Sclerosis Unit, Girona, Spain, (8)University of Bari, Bari, Italy, (9)Univ. Lille, Inserm U1172, CHU Lille, FHU Precise, Lille, France, (10)Partners, Multiple Sclerosis Center, and Center for Neurological Imaging, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, (11)Department of Neurology, University of Colorado, Denver, CO, (12)Multiple Sclerosis Center, Department of Neurology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China, (13)Novartis Pharma AG, Basel, Switzerland, (14)Novartis Services Inc., East Hanover, East Hanover, NJ, (15)Novartis Pharma GmbH, NÜRNBERG, Germany, (16)Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom - DXM02
How the COVID-19 Pandemic Has Changed Multiple Sclerosis Clinical Practice: Results of a Nationwide Provider Survey
Elizabeth H Morrison, MD, MSEd, Psychiatry & Neuroscience, University of California, Riverside School of Medicine, Riverside, CA, Katelyn Michtich, MBA, National Multiple Sclerosis Society, Southern California & Nevada Chapter, Los Angeles, CA and Carrie M Hersh, DO, MS, Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV - DXM03
Characterizing Socioeconomic, Lifestyle, and Comorbidity Mediators of Racial Disparities in Ambulatory Impairments in Multiple Sclerosis.
Farren B.S. Briggs, PhD, ScM1, Erika S. Trapl, PhD1, Devon Conway, MD, MS2 and Douglas D. Gunzler, PhD3, (1)Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, (2)Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, (3)Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH - DXM04
Optical Coherence Tomography As a Biomarker for Multiple Sclerosis Studies
Grace Levy-Clarke, MD1, Carrie Levy, PhD1, Gregory Flippen, DO1, Lauren David, Study Coordinator1, Edouard-Hugh Clarke, JD1 and Mark Cascione, MD2, (1)Ophthalmology, Tampa Bay Uveitis Center, LLC, Safety Harbor, FL, (2)Tampa Neurology Associates, Tampa, FL - DXM05
Associations of Structural Visual Metrics with Moderate to Vigorous Physical Activity in Youth with Pediatric Onset Neuroinflammatory Disorders
Juweiriya Ahmed, MSc1, Samantha Stephens, PhD1, Mina Ly, BSc, MSc1, Giulia Longoni, MD2 and E. Ann Yeh, MD, MA, FRCPC, Dip ABPN2, (1)Department of Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada, (2)Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, Toronto, ON, Canada - DXM06
Treating Minority Patients with Multiple Sclerosis: Development of the CHIMES Trial Mitzi J Williams, MD1, Lilyana Amezcua, MD2, Timothy Vartanian, MD, PhD3, Gregory F Wu, MD, PhD4, Nancy L Monson, PhD5, Evanthia Bernitsas, MD6, Christopher Harp, PhD7, Xiaoming Jia, MD, MEng7, Jinglan Pei, PhD7, Juan Acosta, MD7, Fabio Magrini, MD7 and Anthony T Reder, MD8, (1)Joi Life Wellness MS Center, Atlanta, GA, (2)Keck School of Medicine, University of Southern California, Los Angeles, CA, (3)Weill Cornell Medicine, New York, NY, (4)School of Medicine, Washington University in St. Louis, St. Louis, MO, (5)Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX, (6)Neurology, Wayne State University School of Medicine, Detroit, MI, (7)Genentech, Inc., South San Francisco, CA, (8)University of Chicago Neurology, Chicago, IL - DXM07
Prevalence of Cannabis Use and Associated Factors Among People with Multiple Sclerosis: A 2020 NARCOMS Survey
Robert J. Fox, MD1, Amber Salter, PhD2, Gary Cutter, PhD3, Kate Nichol, PhD4, Joshua R. Steinerman, MD4 and Karry Smith, PhD, MPH4, (1)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (2)Washington University School in St. Louis, St Louis, MO, (3)The University of Alabama at Birmingham, Birmingham, AL, (4)Greenwich Biosciences, Inc., Carlsbad, CA - DXM08
COVID-19 in Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease Patients in North America
Scott D. Newsome, DO, MSCS, FAAN, FANA, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, Anne H. Cross, MD, Neurology, Washington University School of Medicine, St Louis, MO, Robert J. Fox, MD, Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, June Halper, MSN, APN-C, MSCN, FAAN, Consortium of Multiple Sclerosis Centers, Hackensack, NJ, Pamela Kanellis, PhD, MS Society of Canada, Toronto, ON, Canada, Bruce Bebo, PhD, National Multiple Sclerosis Society, New York, NY, David KB Li, MD FRCPC, Radiology and Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, Gary Cutter, PhD, Biostatistics, University of Alabama at Birmingham, Birmingham, AL, Kottil Rammohan, MD, Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL and Amber Salter, PhD, UT Southwestern Medical Center, Dallas, TX
Neuroimaging
- IMG01
Upper Cervical Spinal Cord Myelin Content and Atrophy across the Spectrum of MS Subtypes
Akash Chopra, BSc, Medicine, UBC, Vancouver, BC, Canada, Enedino Hernández-Torres, PhD, Danish Research Centre for Magnetic Resonance, Copenhagen, Denmark, Irene Margaret Vavasour, PhD, University of British Columbia, Vancouver, BC, Canada, Shelly Au, PhD, UBC, Vancouver, BC, Canada, Larry Lynd, PhD, . Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, Scott B. Patten, MD, PhD, University of Calgary, Calgary, AB, Canada, Alexandre Prat, MD, Department of Neurosciences, Université de Montréal, Montréal, QC, Canada, Roger Tam, PhD, Radiology & School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada, Jiwon Oh, MD PhD FRCPC, Medicine, Division of Neurology, St. Michael’s Hospital, Univ of Toronto, Toronto, ON, Canada, Anthony Traboulsee, MD, FRCPC, Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada and Shannon H. Kolind, PhD, Medicine (Neurology), UBC, Vancouver, BC, Canada - IMG02
A Description of Real-World MRI Acquired in Patients with Multiple Sclerosis: Preliminary Insights from FlywheelMS
Anthony Traboulsee, MD, FRCPC1, Gillian Hanson, ND2, Kieran Mace, PhD2, Steve Tarsa, MS, PhD2, Alex Rovira, MD3, Roland G Henry, PhD4,5, David KB Li, MD FRCPC6, Ryan Gan, PhD, MPH7, Laura Julian, PhD7, Jumaah Goldberg, DPT7, Costas Tsougarakis, MSc7, Katherine Belendiuk, PhD7 and Laura Gaetano, PhD8, (1)Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (2)PicnicHealth, San Francisco, CA, (3)Department of Radiology, Vall d’Hebron University Hospital, Barcelona, Spain, (4)UCSF Neurology, Weill Institute for Neurosciences, San Francisco, CA, (5)Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, (6)Radiology and Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (7)Genentech, Inc., South San Francisco, CA, (8)F. Hoffmann-La Roche Ltd, Basel, Switzerland - IMG03
International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS
Anthony Traboulsee, MD, FRCPC1, Mike Wattjes, MD PhD2, Olga Ciccarelli, MD PhD3, Daniel Reich, MD PhD4, Brenda Banwell, MD5, Nicola De Stefano, MD, PhD6, Christian Enzinger, MD7, Franz Fazekas, MD7, Massimo Filippi, MD8, Jette Frederiksen, MD9, Claudio Gasperini, MD10, Yael Hacohen, MD11, Ludwig Kappos, MD12, David Li, MD, FRCPC13, Kshitij Mankad, MD14, Xavier Montalban, MD, PhD15, Scott D. Newsome, DO, MSCS, FAAN, FANA16, Jiwon Oh, MD PhD FRCPC17, Jacqueline Palace, DM18, Maria A Rocca, MD8, Jaume Sastre-Garriga, MD19, Mar Tintoré, MD, PhD20, Hugo Vrenken, PhD21, Tarek Yousry, MD22, Frederik Barkhof, MD, PhD23 and Alex Rovira, MD24, (1)Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (2)Department of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany, (3)Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom, (4)Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, (5)Neurology, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (6)University of Siena, Siena, Italy, (7)Neurology, Medical University of Graz, Graz, Austria, (8)Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, Vita-Salute San Raffaele University, Milan, Italy, (9)Neurology, Rigshospitalet, Glostrup – University Hospital of Copenhagen, Copenhagen, Denmark, (10)Neurology, San Camillo-Forlanini Hospital, Roma, Italy, (11)Faculty of Brain Sciences, University College London Queen Square Institute of Neurology, London, United Kingdom, (12)Mellen Centre for Multiple Sclerosis, Basel, Switzerland, (13)Radiology and Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (14)Neuroradiology, Great Ormond Street Hospital for Children, London, United Kingdom, (15)University Hospital, Barcelona, Spain, (16)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (17)Medicine, Division of Neurology, St. Michael’s Hospital, Univ of Toronto, Toronto, ON, Canada, (18)NMO Service, John Radcliffe Hospital, Oxford, United Kingdom, (19)Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, (20)University Hospital Vall d’Hebron, Barcelona, Spain, (21)Radiology & Nuclear Medicine, Amsterdam UMC, Amsterdam, Netherlands, (22)Lysholm Department of Neuroradiology, UCLH National Hospital for Neurology and Neurosurgery, Neuroradiological Academic Unit, UCL Institute of Neurology, London, United Kingdom, (23)Institutes of Neurology and Healthcare Engineering, UCL, London, United Kingdom, (24)Section of Neuroradiology, Department of Radiology, Hospital Universitari Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain - IMG04
Improving the Utilization of Standardized Mris in Multiple Sclerosis Care: A Pragmatic Trial Perspective
Blake E Dewey, MSE1, Sandra D Cassard, ScD2, Ann Fishman, MBA3, Lianrui Zuo, MSE1, Yufan He, BS4, Aaron Carass, MS5, Jerry L Prince, PhD1, Ellen M Mowry, MD, MCR2 and Scott D. Newsome, DO, MSCS, FAAN, FANA2, (1)Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD, (2)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (3)Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins School of Medicine, Baltimore, MD, (4)Electrical and Computer Engineering, Johns Hopkins University, Baltimore, CA, (5)Computer Science, Johns Hopkins University, Baltimore, MD - IMG05
Accurate Cervical Spinal Cord Area Measurements Can be Extracted from Brain Images
Kamyar Taheri, B.Sc.1, Irene Vavasour, PhD2, Shawana Abel, M.Sc.3, Lisa Lee, M.Sc.3, Poljanka Johnson, B.Sc.3, Stephen Ristow, B.Sc.3, Roger Tam, PhD4, Cornelia Laule, PhD5, Nathalie Ackermans, MD3, Alice Schabas, MD3, Helen Cross, MD3, Jillian Chan, MD3, Ana-Luiza Sayao, MD6, Virender Bhan, MD3, Virginia Devonshire, MD2, Robert Carruthers, MD6, David Li, MD, FRCPC3, Anthony Traboulsee, MD, FRCPC7, Adam Dvorak, B.Sc.3 and Shannon Kolind, PhD7, (1)Medicine, The University of British Columbia, Vancouver, BC, Canada, (2)University of British Columbia, Vancouver, BC, Canada, (3)The University of British Columbia, Vancouver, BC, Canada, (4)Radiology & School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada, (5)Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada, (6)Neurology, University of British Columbia, Vancouver, BC, Canada, (7)Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada
Psychosocial
- PSY01
Social-Cognitive Correlates of Physical Activity in Fatigued and Non-Fatigued Persons with Multiple Sclerosis
Brenda Jeng, MS1, Katie LJ Cederberg, PhD2, Trinh LT Huynh, MPH1, Petra Silic, BS1, Corey D Feasel, M.Ed.1, Catherine D Jones, MSPH1, E M Sikes, PhD3, Jessica F Baird, PhD1, Stephanie L Silveira, PhD4, Jeffer E Sasaki, PhD5 and Robert W Motl, PhD1, (1)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, (3)Occupational Therapy, Shenandoah University, Leesburg, VA, (4)Kinesiology, University of North Texas, Denton, TX, (5)Sports Sciences, Universidade Federal do Triângulo Mineiro, Uberaba, Brazil - PSY02
Health-Related Quality of Life across the Lifespan in Persons with Multiple Sclerosis and Healthy Controls
Corey D Feasel, M.Ed.1, Brenda Jeng, MS1, Brian M Sandroff, PhD2, Katie LJ Cederberg, PhD3, Morghen Sikes, PhD, OT4, Catherine D Jones, MSPH1, Stephanie L Silveira, PhD5, Jessica F Baird, PhD1 and Rob Motl, PhD1, (1)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)Kessler Foundation, East Hanover, NJ, (3)Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, (4)Physical Therapy, UAB, Birmingham, AL, (5)Kinesiology, University of North Texas, Denton, TX - PSY03
The Art of the Patient Conversation: Advanced Practice Provider Perspectives to Improve Outcomes in Multiple Sclerosis
Cortnee Roman, MSN, FNP-BC, Rocky Mountain Multiple Sclerosis Clinic and Research Group, Salt Lake City, UT, Leah Gaedeke, FNP, Providence Multiple Sclerosis Center, Portland, OR, Celeste Fine, FNP-C, Gilbert Neurology, Gilbert, AZ, Katrina Bawden, FNP-C, Rocky Mountain MS Clinic and Research Group, Salt Lake City, UT, Denise R. Bruen, MSN, University of Virginia, James Q. Miller MS Center of Excellence, Charlottesville, VA, Lisa M. Fox, PA-C MPAS, Neurology/Neuroimmunology, Johns Hopkins Medical Center, Baltimore, MD, Meagan A. Adamson, FNP-BC, Neurology Center of Fairfax, Ltd., Fairfax, VA and Bryan Walker, MHS, PA-C, Duke University Division of MS and Neuroimmunology, Durham, NC - PSY04
Living with Multiple Sclerosis: Perceptions, Conflicts and Coping
Dinika Anand, Masters, New Delhi, India, Soumi Awasthy, PhD, Defence Institute of Psychological Research, New Delhi, India and Rajiv Anand, MD, Dr. B.L.Kapoor Superspeciality Hospital, New Delhi, India - PSY05 Cogeval in the Real World: Feasibility, Implementation, and Practical Implications John F Kramer, PA-C, Neurology, St Thomas Medical Partners, Nashville, TN
- PSY06
No One Really Plans to Have MS: Transition Readiness and Quality of Life in Pediatric Multiple Sclerosis
Julissa M Veras, BA1, Estherline Thoby, DO2, Spandana Nallapati, MD3, Manuel Jimenez, MD2,3 and Vikram Bhise, MD4, (1)Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, (2)Pediatrics, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ, (3)Developmental and Behavioral Pediatrics, Children’s Specialized Hospital, New Brunswick, NJ, (4)Pediatric Neurology, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ - PSY07
Association between Cognition and Social Role Participation Among Patients with Multiple Sclerosis
Maryam Hassanein, MPH1,2, Olivia Kaczmarek, BS3, Avtej Sethi, MS2, Barbara Bumstead, MS, ANCP, MSCN2, Marijean Buhse, NP-C, PhD3, Myassar Zarif, MD3 and Mark Gudesblatt, MD4, (1)Stony Brook University, Stony Brook, NY, (2)South Shore Neurologic Associates, P.C., Patchogue, NY, (3)South Shore Neurologic Associates, Patchogue, NY, (4)South Shore Neurologic Associates, P.C., Islip, NY - PSY07
Association between Cognition and Social Role Participation Among Patients with Multiple Sclerosis
Maryam Hassanein, MPH1,2, Olivia Kaczmarek, BS3, Avtej Sethi, MS2, Barbara Bumstead, MS, ANCP, MSCN2, Marijean Buhse, NP-C, PhD3, Myassar Zarif, MD3 and Mark Gudesblatt, MD4, (1)Stony Brook University, Stony Brook, NY, (2)South Shore Neurologic Associates, P.C., Patchogue, NY, (3)South Shore Neurologic Associates, Patchogue, NY, (4)South Shore Neurologic Associates, P.C., Islip, NY - PSY08
Exploring the Impact of the COVID-19 Pandemic on Social Isolation and Mental Health in People with MS
Shu Ling, Ph.D., Cleveland Clinic, Cleveland, OH, Brandon Moss, MD, Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, Zhini Wang, MS, Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH and Amy B Sullivan, PsyD, ABPP, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH
Rehabilitation
- REH01
Stakeholder Recommendations for a Dyadic Physical Activity Intervention for People with Moderate-to-Severe Multiple Sclerosis and Their Care-Partners: A Modified e-Delphi Study.
Afolasade Fakolade, PhD1, Odessa J. McKenna, MSc2, Rachel Kamel, BSc(c)3, Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC4, Marcia Finlayson, PhD1, Amy Latimer-Cheung, PhD5 and Lara A. Pilutti, PhD2, (1)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, (2)Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada, (3)University of Ottawa, Ottawa, ON, Canada, (4)University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (5)School of Kinesiology and Health Studies, Queen’s University, Kingston, ON, Canada - REH02
Effects of Weekly Participation in a Wellness Program on People Living with Multiple Sclerosis: A Three-Year Analysis
Brian Hutchinson, PT, MSCS1, John Schafer, MD2, Lacey Sayre, CNA3 and Tiffany Malone, MSW, MSCS3, (1)Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA, (2)Mercy MS Center, Carmichael, CA, (3)Multiple Sclerosis Achievement Center, Dignity Health, Citrus Heights, CA - REH03
Using Seating and Wheeled Mobility to Manage MS Symptoms
Caroline Portoghese, OTR/L, ATP/SMS, MSCS, Rehab, Handi Medical Supply, Saint Paul, MN; OTA Faculty, St. Catherine University, Saint Paul, MN; OTD Teaching Specialist, University of Minnesota, Minneapolis & Rochester, MN - REH03
Using Seating and Wheeled Mobility to Manage MS Symptoms
Caroline Portoghese, OTR/L, ATP/SMS, MSCS, Rehab, Handi Medical Supply, Saint Paul, MN; OTA Faculty, St. Catherine University, Saint Paul, MN; OTD Teaching Specialist, University of Minnesota, Minneapolis & Rochester, MN - REH03
Using Seating and Wheeled Mobility to Manage MS Symptoms
Caroline Portoghese, OTR/L, ATP/SMS, MSCS, Rehab, Handi Medical Supply, Saint Paul, MN; OTA Faculty, St. Catherine University, Saint Paul, MN; OTD Teaching Specialist, University of Minnesota, Minneapolis & Rochester, MN - REH04
Spasticity Experience in Adults with Multiple Sclerosis: An Integrated Conceptual Model
Michelle H. Cameron, MD, PT, MCR1, Joanne Wagner, PT, PhD2, Francois Bethoux, MD3, Edelle Field-Fote, PT, PhD, FAPTA, FASIA4,5, William R. Lenderking, PhD6, Erica Zaiser, PhD7, Katelyn N. Cutts, MS6 and Joshua R. Steinerman, MD2, (1)Department of Neurology, Oregon Health & Science University, Portland, OR, (2)Greenwich Biosciences, Inc., Carlsbad, CA, (3)Department of Physical Medicine and Rehabilitation, Cleveland Clinic, Cleveland, OH, (4)Spinal Cord Injury Research at the Shepherd Center, Atlanta, GA, (5)Department of Rehabilitation Medicine, Emory University School of Medicine, Atlanta, GA, (6)Evidera, Waltham, MA, (7)Evidera, London, United Kingdom - REH05
The Effect of Telerehabilitation on the Quality of Life and Fatigue of Patients with Multiple Sclerosis
Juliana Rhein, Juliana Rhein1, Alice Estevo Dias, Speech-Language Pathologist /PhD2, Anna Elisa Moraes Sr., physicaltherapist3, Francis Fávero, physicaltherapist3 and Acary Bulle Sr., doctor4, (1)Rehabilitation, associação brasileira de esclerose múltipla, São Paulo/SP, Brazil, (2)Scientific Research, Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil, (3)neurologia, universidade federal de são paulo, São Paulo, Brazil, (4)neurology, universidade federal de são paulo, São Paulo, Brazil - REH06 The Use of Ekso GT Exoskeleton Yields Functional Gait Improvement in Patients with Multiple Sclerosis Ryan Lovell, PT, DPT, NCS, ATP, Casa Colina Hospital, Pomona, CA
- REH07
Beyond the Physical Symptoms of Spasticity for Persons with MS Spasticity: Results from SEEN-MSS, a Large-Scale, Self-Reported Survey
Scott D. Newsome, DO, MSCS, FAAN, FANA1, Ben Thrower, MD2, Barry Hendin, MD3, Joanne Wagner, PT, PhD4, Sherry Danese, PhD5 and Jenifer Patterson, ARNP, MSCN4, (1)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (2)Andrew C. Carlos MS Institute, Shepherd Center, Atlanta, GA, (3)Neurology, University of Arizona, Tucson, AZ, (4)Greenwich Biosciences, Carlsbad, CA, (5)Outcomes Insights, Agoura Hills, CA - REH08 Frequency and Characteristics of Falls in People Living with and without Multiple Sclerosis during the COVID-19 Pandemic: An Online Survey Tobia Zanotto, PhD1, Mikaela L Frechette, MS2, Stephen R Koziel, MPH2, Katherine L Hsieh, PhD2 and Jacob J Sosnoff, PhD3, (1)Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, (2)Department of Kinesiology and Community Health, university of illinois at urbana champaign, urbana, IL, (3)Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL
Complementary and Alternative Therapies
Case Reports / Case Series
Disease-modifying Therapy
Epidemiology and Genetics
Family and Caregivers
Internet and Information Services
Imaging
Multidisciplinary Care
Methods of Care
Neuroimmunology and Disease Models
Non-imaging Biomarkers
Neurophysiology; Neuropsychology and Neuropsychiatry
Neuropathology and Pathogenesis
Programs
Psychosocial Factors
Quality of Life
Rehabilitation
Relapse Therapy
Self-care
Symptom Management
Complementary and Alternative Therapies
- CAM01
Remote Art Therapy Activities Proposal during a COVID-19 Pandemic in Multiple Sclerosis
Alice E Dias, Dr1, Teresa K Teng, Ms2 and Margareth MT Zampieri, Ms2, (1)Scientific Research, Brazilian Multiple Sclerose Association (ABEM), São Paulo, Brazil, (2)Alternative / complementary therapies, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil - CAM02
Evaluation of a 6 Week Integrative Medicine Workshop Series on Quality of Life, Self-Efficacy and Wellness in MS
Megan Weigel, DNP, APRN, MSCN, APHN1,2,3, Linda Connelly, PhD, MSH, ARNP, CNOR1 and Mehgan Fox, BSH2, (1)Brooks College of Health, School of Nursing, University of North Florida, Jacksonville, FL, (2)First Coast Integrative Medicine, Jacksonville, FL, (3)oMS Yoga, Inc., Jacksonville Beach, FL - CAM03
Mindfulness Based Art Therapy to Improve Symptoms Among Adults with Multiple Sclerosis
Pamela K Newland, PhD, RN, Goldfarb School of Nursing, St Louis, IL, Karlie Lading, BS, RN, nursing, Goldfarb School of Nursing, St Louis, MO and Ling Chen, PhD, Biostatistics, Washington University St Louis, St Louis, MO
Case Reports / Case Series
- CSR01
Delayed Visual Improvement in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis
Alexandra B Kornbluh, MD1, Grant T Liu, MD2 and Sarah E Hopkins, MD, MSPH1, (1)Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA, (2)Ophthalmology, Children’s Hospital of Philadelphia, Philadelphia, PA - CSR02
Non-Intensive Exercise to Prepare for Intensive, Task-Oriented Rehabilitation in People with Progressive Multiple Sclerosis: A Two-Participant Case Study
Cameron S Mang, PhD1, Kristen E Plandowski, BSc1, Eduardo A Toledo-Aldana, BSc1 and Sarah J Donkers, PT, PhD2, (1)Kinesiology and Health Studies, University of Regina, Regina, SK, Canada, (2)School of Rehabilitation Science, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada - CSR03
Long Arm Serial Casting Results in Decreased Spasticity and Improved Function for Woman with MS
Christine Hampton, MOT, OTR/L, Shepherd Center, Atlanta, GA - CSR04
Positive Outcome with Alemtuzumab in Hispanic Puerto Rican Woman with Highly Active Multiple Sclerosis after Various Failed Disease Modifying Therapies
Evián Pérez Rivera, BS1, Mayra I González Torres, BS1, Ashley N García Aponte, BS1, Viviana Martinez Maldonado, BS2, Ramón Vega Corteguera, BS2, Ivonne Vicente Loperena, MD2 and Angel Chinea, MD3, (1)San Juan Bautista School of Medicine, Caguas, PR, (2)San Juan Multiple Sclerosis Center, Guaynabo, PR, (3)San Juan MS Center, Guaynabo, PR, Puerto Rico - CSR05
Immunotherapy-Responsive Post COVID-19 Central Nervous System Inflammatory Syndrome, a Case Report
Gina S Perez, MD, Courtney Iser, MD, Sara Habib, MD, Juliane Chainakul, APRN-CNS, Sarah Durica, MD, Danny Samkutty, MD, Evgeny Sidorov, MD, Ahmad Al Awwad, MD, Masoom Desai, MD, Jorge Ortiz, MD, Nidhiben Anadani, MD and David Gordon, MD, Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK - CSR06
Case Report: Lama-2 Related Muscular Dystrophy Mimicking Multiple Sclerosis
Jacqueline Koshorek, DO and Shiv Saidha, MBBCh, MD, MRCPI, Neurology, Johns Hopkins University, Baltimore, MD - CSR07
Case Report of a Severe Cutaneous Lupus Erythematosus Flare in a Patient Treated with Eculizumab for the Treatment of Neuromyeltis Optica Spectrum Disorder
Jennifer Chester, FNP-BC, MSCN1, Leah Hurd, RN, BSN2, Tyler Kaplan, MD3,4, Mark Box, MD5 and Jeffrey Kaplan, MD2, (1)Kansas City MS Center at College Park Specialty, Overland Park, KS, (2)Kansas City MS Center, College Park Neurology, Overland Park, KS, (3)Rush University Medical Center, Chicago, United States Minor Outlying Islands, (4)University of Utah, Salt Lake City, UT, (5)Rheumatology, Carondolet, Kansas City, MO - CSR08 Bad Lettuce? Frozen Vegetables? Undercooked Steak? Case Report of Systemic Listeria Monocytogenes Infection in a Patient on Dimethyl Fumarate Lisa M. Fox, PA-C MPAS, Neurology/Neuroimmunology, Johns Hopkins Medical Center, Baltimore, MD and Scott D. Newsome, DO, MSCS, FAAN, FANA, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
- CSR09
Treatment Resistant Tinea Corporis in Multiple Sclerosis Patients Treated with Ocrelizumab
Michelle Maynard, PharmD, BCPS, Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI, Carmen Raschka, RN, Neurosciences, Froedtert Hospital, Milwaukee, WI, Mokshal H Porwal, BSc, Medical College of Wisconsin, Milwaukee, WI and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI - CSR10 Identifying and Treating Steroid-Induced Psychosis in MS Patients Using Quetiapine Olinka K Hrebicek, MD, Neurology, Island Health MS Clinic, Victoria, BC, Canada and Niall I Murphy, BSc, University of Victoria, Victoria, BC, Canada
- CSR11
Multiple Sclerosis-like Features in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Red Flag, Red Herring, or Regular Occurrence?
Samuel B Marcucci, BS1, Rosemarie Walch, DO1, Ameneh Zare-Shahabadi, MD/MPH2, Lawrence P Goldstick, MD1, Allison Jordan, DO1, Roman Kassa, MD/PhD1, Abdelkader Mahammedi, MD3 and Aram Zabeti, MD1, (1)Waddell Center for Multiple Sclerosis, University of Cincinnati, Cincinnati, OH, (2)Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, (3)Department of Radiology, University of Cincinnati, Cincinnati, OH - CSR12
Multiple Sclerosis in a Patient with Neurofibromatosis Type-1
Siddharth Ninan, MBBS1, Gershon Timothy, MD, PhD1, Robert Greenwood, MD1, Clara Zelasky, PA-C1, Stephanie Iyer, PharmD, CPP2 and Irena Dujmovic-Basuroski, MD1, (1)Department of Neurology, UNC Hospitals, Chapel Hill, NC, (2)Department of Pharmacy, UNC Hospitals, Chapel Hill, NC
Disease-modifying Therapy
- DMT08
Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
Xavier Montalban, MD, PhD1, Douglas L. Arnold, MD2, Martin S Weber, MD3, Ivan Staikov, MD, PhD4, Karolina Piasecka-Stryczynska, PhD5, Emily C. Martin, PhD6, Matthew Mandel, MD7, Fernando Dangond, MD, MBA6 and Jerry S Wolinsky, MD8, (1)Vall d’Hebron University Hospital, Barcelona, Spain, (2)McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital, McGill University, Montreal, QC, Canada, (3)Neurologie & Neuropathologie, Universitie Göttingen, Göttingen, Germany, (4)Department of Neurology, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria, (5)Department of Neurology and Cerebrovascular Diseases, Poznan University of Medical Sciences, Poznan, Poland, (6)EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, Rockland, MA, (7)EMD Serono Research & Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt, Germany), Billerica, MA, (8)McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX - DMT09
Assessment of Composite Disability Accumulation of Ponesimod Relative to Teriflunomide in the Optimum Phase 3 Study
Alexander J. Keenan, MA, MHP, Ibrahim Turkoz, PhD, Robert Murray, MS and Maria Ait Tihyaty, PhD, Janssen Research & Development, Titusville, NJ - DMT10
MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity
Alexander Keenan, MD1, Ibrahim Turkoz, PhD1, Robert Murray, MS2 and Maria Ait Tihyaty, PhD1, (1)Janssen Research & Development, Titusville, NJ, (2)Janssen Research & Development LLC, High Wycombe, NJ, United Kingdom - DMT11
Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs)
Amanda Hickman, PharmD, MPH, MSCS, Central Support Team, Trellis Rx, Atlanta, GA - DMT12
Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Amy Perrin Ross, APN, MSN, CNRN, MSCN1, Thomas Berger, MD, MSc2, Robert A Bermel, MD3, Bruno Brochet, MD4, Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC5, Trygve Holmøy, MD, PhD6,7, Rana Karabudak, Prof., MD8, Joep Killestein, MD, PhD9, Carlos Nos, MD10, Francesco Patti, MD, PhD11, Ludo Vanopdenbosch, MD12, Timothy Vollmer, MD13, Regine Buffels, MD14, Karen Kadner, MD, PhD14, Thomas Kuenzel, PhD14, Hans-Peter Hartung, M.D.2,15,16 and on behalf of the ENSEMBLE Investigators and Steering Committee, (1)Loyola University Chicago, Chicago, IL, (2)Department of Neurology, Medical University of Vienna, Vienna, Austria, (3)Mellen Center for MS, Cleveland Clinic, Cleveland, OH, (4)University of Bordeaux, Bordeaux, France, (5)University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (6)Department of Neurology, Akershus University Hospital, Lørenskog, Norway, (7)Institute of Clinical Medicine, University of Oslo, Oslo, Norway, (8)Department of Neurology, Hacettepe University Faculty of Medicine, Ankara, Turkey, (9)Department of Neurology, VU University Medical Center, Amsterdam, Netherlands, (10)Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Vall d’Hebron Hospital Universitari, 08035, Barcelona, Spain, (11)GF Ingrassia, Department, Neuroscience Section, University of Catania, Catania, Italy, (12)Department of Neurology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, (13)Department of Neurology, University of Colorado School of Medicine, Aurora, CO, (14)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (15)Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, (16)Brain and Mind Centre, University of Sydney, Sydney, Australia - DMT13
Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab
Anne H. Cross, MD1, Silvia Delgado, MD2, Mario Habek, MD3, Maria Davydovskaya, PhD4, Natalia Totolyan, MD5, Ratnakar Pingili, MBBS6, Linda Mancione, BA6, Roseanne Sullivan, PharmD6, Martin Zalesak, MD, PhD7, Wendy Su, PhD8, Krishnan Ramanathan, PhD7, Xavier Montalban, MD, PhD9 and Kevin Winthrop, MD MPH10, (1)Neurology, Washington University School of Medicine, St Louis, MO, (2)Neurology, University of Miami Miller School of Medicine, Miami, FL, (3)University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia, (4)Pirogov Russian National Research Medical University, Moscow, Russian Federation, (5)National Medical University, St Petersburg, Russian Federation, (6)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (7)Novartis Pharma AG, Basel, Switzerland, (8)Autoimmune, TG Therapeutics, Inc, New York, NY, (9)Vall d’Hebron University Hospital, Barcelona, Spain, (10)School of Public Health at Oregon Health & Science University, Portland, OR - DMT14
Immunoglobulin Kinetics and Infection Risk after Long-Term Inebilizumab Treatment for Neuromyelitis Optica Spectrum Disorder
Benjamin Greenberg, MD1, Dewei She, Ph.D.2, Eliezer Katz, M.D.2 and Bruce A.C. Cree, MD, PhD, MAS3, (1)Department of Neurology, University of Texas Southwestern, Dallas, TX, (2)Viela Bio, Gaithersburg, MD, (3)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA - DMT15
Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years
Bruce A.C. Cree, MD, PhD, MAS1, Gavin Giovannoni, MD, PhD2, Ralf Gold, MD3, Robert J. Fox, MD4, Patrick Vermersch, MD, PhD5, Ralph H.B. Benedict, PhD6, Amit Bar-Or, MD7, Nicolas Rouyrre, MSc8, Daniela Piani-Meier, PhD8, Shannon Ritter, MS9, Ajay Kilaru, MBBS8, Frank Dahlke, MD8, Goeril Karlsson, PhD8 and Ludwig Kappos, MD10, (1)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (2)Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, (3)Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, (4)Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, (5)Univ. Lille, Inserm U1172, CHU Lille, FHU Precise, Lille, France, (6)Jacobs Multiple Sclerosis Center, University at Buffalo, Buffalo, NY, (7)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (8)Novartis Pharma AG, Basel, Switzerland, (9)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (10)Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland - DMT16
Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders
Calin Dumitrescu, Medical Student Scholar, Neurology, Medical College of Wisconsin, Milwaukee, WI, Amber Salter, PhD, Biostatistics, Washington University in St. Louis, St. Louis, MO, Michelle Maynard, PharmD, BCPS, Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI - DMT17
Safety of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis with Suboptimal Response to Prior Disease-Modifying Therapies: Data from the CASTING Study
Celia Oreja-Guevara, MD1, Heinz Wiendl, MD2, Aksel Siva, MD, FEAN3, Karen Kadner, MD, PhD4, Thomas Kuenzel, PhD4, Regine Buffels, MD4 and Patrick Vermersch, PhD5, (1)Hospital Clinico San Carlos, Madrid, Spain, (2)Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany, (3)Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey, (4)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (5)University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Imminent, Lille, France - DMT18
Baseline Characteristics and Adherence Among Multiple Sclerosis Patients Initiating Siponimod in Real World
Chinmay Deshpande, PhD, BPharm1, Mengru Wang, MS2, Roshani Shah, MPH3, Yutong Chang, MS2, Fei Yang, PhD1, Wing Chow, PharmD, MPH1 and Gina M Cox, PhD1, (1)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (2)KMK Consulting, Inc., Morristown, NJ, (3)Previously employed by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, NJ - DMT19
Characterization of Treatment-Naïve Patients with Multiple Sclerosis Newly Initiating Disease-Modifying Therapy
Daniel Kantor, MD1, Timothy Pham, MS2, Xiu Chen, PhD2, Mayank Mittal, PhD2 and Qian Xia, PhD2, (1)Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, (2)Bristol Myers Squibb, Princeton, NJ - DMT20
Number-Needed-to-Treat (NNT) to Prevent One Relapse in Recent Teriflunomide-Controlled Clinical Trials in Relapsing MS
Daniel Kantor, MD, Florida Atlantic University, Boca Raton, FL - DMT21
Number-Needed-to-Harm (NNH) in Alemtuzumab and Ocrelizumab Pivotal Clinical Trials in Relapsing MS
Daniel Kantor, MD, Florida Atlantic University, Boca Raton, FL - DMT22
Click-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)
Augusto A Miravalle, M.D., Advanced Neurology of Colorado, University of Colorado, Fort Collins, CO, Jacob A Sloane, MD PhD, BIDMC Department of Neurology, Harvard Medical School, Boston, MA, Julie Aldridge, MS, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Billerica, MA, Danielle E Harlow, PhD, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Rockland, MA and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA - DMT23
Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder
Dean Wingerchuk, M.D.1, Achim Berthele, MD2, Kazuo Fujihara, MD3,4,5, Celia Oreja-Guevara, MD6, Ho Jin Kim, MD, PhD7, Michael Levy, MD, PhD8,9, Ichiro Nakashima, MD, PhD4,10, Jacqueline Palace, DM11, Shulian Shang, PhD12, Marcus Yountz, MD12, Larisa Miller, PharmD12 and Sean J Pittock, M.D.13, (1)Mayo Clinic, Scottsdale, AZ, (2)Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany, (3)Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, (4)Tohoku University, Sendai, Japan, (5)Fukushima Medical University, Fukushima City, Japan, (6)Hospital Universitario Clinico San Carlos, Madrid, Spain, (7)Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South), (8)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (9)Johns Hopkins University, Baltimore, MD, (10)Tohoku Medical and Pharmaceutical University, Sendai, Japan, (11)John Radcliffe Hospital, Oxford, United Kingdom, (12)Alexion Pharmaceuticals, Boston, MA, (13)Mayo Clinic, Rochester, MN - DMT24
Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies
Denise R. Bruen, MSN1, Meghan Garabedian, CRNP, MSN, MSCN2, Cortnee Roman, MSN, FNP-BC3, Nicholas W. Robinson, MA4, Virginia R. Schobel, MSc4, Jason P. Mendoza, PhD5, James B. Lewin, PharmD5, Mary Zhang, PharmD5 and Sai L. Shankar, PhD5, (1)University of Virginia Neuroscience, Charlottesville, VA, (2)Neurology, Penn Neuroscience Center, Perelmen Center for Advanced Medicine, Philadelphia, PA, (3)Rocky Mountain Multiple Sclerosis Clinic and Research Group, Salt Lake City, UT, (4)Spherix Global Insights, Exton, PA, (5)Biogen, Cambridge, MA - DMT25
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS
Douglas L. Arnold, MD1, James K. Sheffield, MD, MBA, MS2, Xavier Montalban, MD, PhD3, Bruce A.C. Cree, MD, PhD, MAS4, Ludwig Kappos, MD5, Giancarlo Comi, MD6, Hans-Peter Hartung, M.D.7,8,9, Hongjuan Liu, MD2, Chahin Pachai, PhD2, Diego Silva, MD2 and Jeffrey A Cohen, MD10, (1)Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, (2)Bristol Myers Squibb, Princeton, NJ, (3)Hospital Universitario Vall d’Hebron, Barcelona, Spain, (4)UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, (5)Mellen Centre for Multiple Sclerosis, Basel, Switzerland, (6)University Vita-Salute San Raffaele, Milan, Italy, (7)Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine-University Düsseldorf, Dusseldorf, Germany, (8)Department of Neurology, Medical University of Vienna, Vienna, Austria, (9)Brain and Mind Centre, University of Sydney, Sydney, Australia, (10)Cleveland Clinic Mellen Center, Cleveland, OH - DMT26
Acapella: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS, Year Four Data
Elizabeth A Douglas, MPH, Rosie M Jungquist, B.S., Andrew J Bouley, M.D., Ellen S Lathi, M.D. and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA - DMT27
Acapella: Hypogammaglobulinemia and JCV Status in Ocrelizumab-Treated Patients, Year Four Data
Elizabeth A Douglas, MPH, Rosie M Jungquist, B.S., Andrew J Bouley, M.D., Joshua D Katz, M.D. and Ellen S Lathi, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA - DMT28
Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies
Enrique Alvarez, MD, PhD, MSCI1, Kavita V Nair, PhD1, Hiangkiat Tan, MS2, Kapil Rathi, PhD2, Nicole Gabler, PhD2 and Chinmay Deshpande, PhD, BPharm3, (1)Rocky Mountain Multiple Sclerosis Center at the University of Colorado, Aurora, CO, (2)HealthCore Inc., Wilmington, DE, (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ - DMT29
Real-Life Experience with Ocrelizumab in Older Patients at an Academic MS Center
Evan Luxenberg, MD1, Gloria von Geldern, MD1,2, Meghan C Romba, MD1,2, Yujie Wang, MD1,2, Deborah Gallaro, R.Ph.2, Bren Hammond, RN, BSN, MSCN2, Jennie Toro, RN2, Wendy Durand, RN, BSN2, Melissa F Kennedy, RN, C-MSCN2, Samantha Kelly, RN2, Sarika Vyasarayani, RN, BSN2 and Annette Wundes, MD1,2, (1)Neurology, University of Washington, Seattle, WA, (2)University of Washington MS Center, Seattle, WA - DMT30
Multiple Sclerosis Disease Modifying Therapies’ Adherence and Total Medical Costs Among Women with Maternity Services Using Administrative Data.
Francis C Staskon, PhD, MS1, Heather Kirkham, PhD, MPH1 and Kathleen Love, RN, BA2, (1)HealthCare Analytics, Research & Reporting, Walgreen, Co., Deerfield, IL, (2)Clinical Program Manager, AllianceRx Walgreens Prime, Deerfield, IL - DMT31
Adherence to Multiple Sclerosis Disease Modifying Therapies Using Pharmacy Quality Alliance Criteria and Medical Costs or Hospitalizations in an Administrative Database.
Francis C Staskon, PhD, MS1, Heather Kirkham, PhD, MPH1 and Kathleen Love, RN, BA2, (1)HealthCare Analytics, Research & Reporting, Walgreen, Co., Deerfield, IL, (2)Clinical Program Manager, AllianceRx Walgreens Prime, Deerfield, IL - DMT33
Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study
Heinz Wiendl, MD, Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany, Klaus Schmierer, MD, PhD, The Blizard Institute (Neuroscience), Queen Mary University of London, London, United Kingdom, Suzanne Hodgkinson, MD, Immune Tolerance Group, Ingham Institute for Applied Medical Research, UNSW Medicine, Liverpool, Australia, Tobias Derfuss, MD, Neurology Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine and Biomedicine, University Hospital and University of Basel, Basel, Switzerland, Andrew Chan, MD, Ambulantes Neurozentrum, Inselspital, Bern, Switzerland, Finn Sellebjerg, MD, Department of Neurology, Multiple sclerosis & Neuroimmunology Division, University of Texas Southwestern Medical Center, Dallas, TX, Anat Achiron, MD, PhD, Sheba Medical Center, Ramat Gan, Israel, Xavier Montalban, MD, PhD, Division of Neurology, St Michael’s Hospital, University of Toronto, Toronto, ON, Canada, Alexandre Prat, MD, Department of Neurosciences, Université de Montréal, Montréal, QC, Canada, Nicola De Stefano, MD, PhD, University of Siena, Siena, Italy, Frederik Barkhof, MD, PhD, Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom; Department of Radiology, VU University Medical Center, Amsterdam, Netherlands, Letizia Leocani, MD, Ospedale San Raffaele, Milano, Italy, Patrick Vermersch, PhD, University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Imminent, Lille, France, Anita Chudecka, MA, Cytel, Inc., Cambridge, MA, Sanjeev Roy, MD, Merck KGaA, Darmstadt, Germany, Aubonne, Switzerland and Ursula Boschert, PhD, Merck KGaA, Darmstadt, Germany, Eysins, Switzerland - DMT34
Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 Experience–US Study
Jacob A Sloane, MD PhD1, Kyle E. Smoot, MD2, Bianca Weinstock-Guttman, MD3, Sibyl Wray, MD4, Miguel Rosales, MSc5, Sai L. Shankar, PhD5, Justin Bohn, ScD5, Catherine Miller, PharmD, MPH5, Jordan Messer, PharmD5, Jason P. Mendoza, PhD5 and James B. Lewin, PharmD5, (1)Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, (2)Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR, (3)Jacobs Multiple Sclerosis Center for Treatment and Research, Jacobs School of Medicine and Biomedical Science, University at Buffalo, Buffalo, NY, (4)Hope Neurology, Knoxville, TN, (5)Biogen, Cambridge, MA - DMT35
COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths
Jakai Nolan, DO, MPH1, Jacqueline Nicholas, MD, MPH1, Andrew Smith, MD1, Irene Koulinska, MD, ScD2, Arman Altincatal, MS2, Cyndi Grossman, PhD2, Scott Husak, Statistical Programmer3, Kedar Mahajan, MD, PhD3, Robert A Bermel, MD4, Jeff Cohen, MD3 and Brandon Moss, MD5, (1)OhioHealth, Columbus, OH, (2)Biogen, Cambridge, MA, (3)Cleveland Clinic, Cleveland, OH, (4)Mellen Center for MS, Cleveland Clinic, Cleveland, OH, (5)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH - DMT36
Real World Experience with Systemic Injection Reactions to Ofatumumab
John F Kramer, PA-C, Neurology, St Thomas Medical Partners, Nashville, TN - DMT37
Updated Post-Approval Safety of Cladribine Tablets in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections and COVID-19
Gavin Giovannoni, MD, PhD, Queen Mary University of London, London, United Kingdom, Joseph Berger, MD, FACP, FAAN, FANA, Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, Thomas P. Leist, MD, Comprehensive Multiple Sclerosis Center, Division of Clinical Neuroimmunology, Jefferson University, Philadelphia, PA, Dominic Jack, PhD, Merck KGaA, Darmstadt, Germany, Andrew Galazka, MD, Merck KGaA, Darmstadt, Germany, Aubonne, Switzerland, Axel Nolting, MD, Merck KGaA, Darmstadt, Germany, Darmstadt, Germany and Doris Damian, PhD, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany, Billerica, MA - DMT38
Natalizumab: Management and Safety during the COVID-19 Pandemic
Judit Díaz-Díaz, MD1, Clara Isabel Ramirez, MD1, Marta Ortiz-Pica, Nurse2, Irene Gómez-Estevez, MD1, Elena García Yusta, Nurse2 and Celia Oreja-Guevara, MD1, (1)Department of Neurology, University Hospital Clinico San Carlos, IdiSSC, Madrid, Spain, (2)Day Care Unit, University Hospital Clinico San Carlos, Madrid, Spain - DMT39
Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a
Kathryn C Fitzgerald, ScD1, Carrie M Hersh, DO, MS2, Lana Zhovtis Ryerson, MD3, Ellen M Mowry, MD, MCR4, Shirley Liao, PhD5, Arman Altincatal, MS5 and Maria L Naylor, PhD5, (1)Johns Hopkins Medicine, Department of Neurology, Baltimore, MD, (2)Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, (3)NYU Grossman School of Medicine, Department of Neurology, New York, NY, (4)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (5)Biogen, Cambridge, MA - DMT40
Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem
Krupa Pandey, MD1, Kathryn Giles, MD, MSc, FRCPC2, Konstantin Balashov, MD, PhD3, Richard Macdonell, MD4, Jörg Windsheimer, MD5, Annette F Okai, MD6, Mikel Martinez, MD7, Oksana Mokliatchouk, PhD8, Jennifer Lyons, MD8, Shivani Kapadia, PharmD, RPh8 and Nicholas J Everage, PhD8, (1)Hackensack University Medical Center, Hackensack, NJ, (2)Cambridge Memorial Hospital, Cambridge, ON, Canada, (3)Boston Medical Center and Boston University, Boston, MA, (4)Department of Neurology, Austin Health, University of Melbourne, Melbourne, VIC, Australia, (5)Praxis fur Neurologie und Psychiatrie, Nurnberg, Germany, (6)Multiple Sclerosis Treatment Center of Dallas, Dallas, TX, (7)Centre Hospitalier Dax, Dax, France, (8)Biogen, Cambridge, MA - DMT41
Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the Expand Study
Le H. Hua, MD1, Amit Bar-Or, MD2, Fred D. Lublin, MD3, Xiangyi Meng, PhD4, Gina Mavrikis Cox, PhD4, Bruce A.C. Cree, MD, PhD, MAS5 and Robert J. Fox, MD6, (1)Lou Ruvo Center for Brain Health, Las Vegas, NV, (2)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (3)Icahn School of Medicine at Mount Sinai, New York, NY, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, (6)Cleveland Clinic, Cleveland, OH - DMT42
Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models
Le H. Hua, MD1, Roshani Shah, MS2, Gina Mavrikis Cox, PhD2, Tim Bancroft, PhD3, Rachel Halpern, PhD3 and Miriam G. Cisternas, MA3, (1)Lou Ruvo Center for Brain Health, Las Vegas, NV, (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (3)Health Economics and Outcomes Research, Optum, Eden Prairie, MN - DMT43
Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy
Le H Hua, MD1, Enrique Alvarez, MD, PhD, MSCI2, Roland G Henry, PhD3, Joel Brown, PhD, PharmD4, Elizabeth Camacho, MBA4, Xiangyi Meng, PhD4, Marina Ziehn, PhD5, Brandon Brown, PharmD4 and Benjamin M Greenberg, MD, MHS6, (1)Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, (2)Department of Neurology, University of Colorado, Aurora, CO, (3)UCSF Neurology, Weill Institute for Neurosciences, San Francisco, CA, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)Novartis Pharma AG, Basel, Switzerland, (6)Neurology & Neurotherapeutics – MS Clinic, UT Southwestern Medical Center, Dallas, TX - DMT44
Incidence and Severity of Natalizumab Infusion-Related Reactions during Infusion and Postinfusion Observation
Ling Jin, MD, Zheng Ren, PhD, Prabjot Hunjan, BSc, PgDip, Seth Levin, MD and Stephanie Licata, PhD, Biogen, Cambridge, MA - DMT45
Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties
Marc Bigaud, PhD1, Frank Dahlke, MD1, Thomas Hach, MD1, Daniela Piani-Meier, PhD1 and Ralf Gold, MD2, (1)Novartis Pharma AG, Basel, Switzerland, (2)Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany - DMT46
Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FANA, FAAN, FRCPC1, Hans Guehring, MD2, Zuzana Murgasova, MD2 and Dominic Jack, PhD2, (1)University of Ottawa, Department of Medicine and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (2)Merck KGaA, Darmstadt, Germany - DMT47
Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data
Mark Gudesblatt, MD1, Myassar Zarif, MD1, Barbara Bumstead, MS, ANP-C, MSCN1, Marijean Buhse, NP-C, PhD1, Olivia Kaczmarek, BS1, Jared Srinivasan, BS2, Nuno Barros, PhD3, Annemie Ribbens, PhD3, Wim Van Hecke, PhD3, Elise Digga, BA4, Jason P. Mendoza, PhD2 and Stephen Krieger, MD4, (1)South Shore Neurologic Associates, Patchogue, NY, (2)Biogen, Cambridge, MA, (3)icometrix, Leuven, Belgium, (4)Icahn School of Medicine at Mt. Sinai, New York, NY - DMT48
Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent
Michael Levy, MD, PhD1,2, Achim Berthele, MD3, Ho Jin Kim, MD, PhD4, Kazuo Fujihara, MD5,6,7, Ichiro Nakashima, MD, PhD6,8, Celia Oreja-Guevara, MD9, Jacqueline Palace, DM10, Sean J Pittock, M.D.11, Murat Terzi, MD12, Natalia Totolyan, MD13, Shanthi Viswanathan, MRCP14, Kai-Chen Wang, MD, PhD15,16, Amy Pace, ScD17, Marcus Yountz, MD17, Diane Lawson, PharmD, RPh17, Eva Laudon-Meyer, MD PhD18 and Dean Wingerchuk, M.D.19, (1)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (2)Johns Hopkins University, Baltimore, MD, (3)Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany, (4)Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South), (5)Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, (6)Tohoku University, Sendai, Japan, (7)Fukushima Medical University, Fukushima City, Japan, (8)Tohoku Medical and Pharmaceutical University, Sendai, Japan, (9)Hospital Universitario Clinico San Carlos, Madrid, Spain, (10)John Radcliffe Hospital, Oxford, United Kingdom, (11)Mayo Clinic, Rochester, MN, (12)Ondokuz Mayis University, Samsun, Turkey, (13)National Medical University, St Petersburg, Russian Federation, (14)Kuala Lumpur Hospital, Kuala Lumpur, Malaysia, (15)School of Medicine, National Yang Ming University, Taipei, Taiwan, (16)Cheng-Hsin General Hospital, Taipei, Taiwan, (17)Alexion Pharmaceuticals, Boston, MA, (18)Alexion Pharmaceuticals, Zurich, Switzerland, (19)Mayo Clinic, Scottsdale, AZ - DMT49
Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening – Early 3 Months Post Approval Data
Mitzi J Williams, MD1, Janine Robinson, MS2, Katarzyna Elliott-Maksymowicz, MSc2, Bianca Luscher, BS2 and Chinmay Deshpande, PhD, BPharm3, (1)Joi Life Wellness Group, LLC, Smyrna, GA, (2)W2O Group, Philadelphia, PA, (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ - DMT50
Alopecia in Multiple Scleoris Patients Treated with Disease Modifying Therapies
Mokshal H Porwal, BSc, Medical College of Wisconsin, Milwaukee, WI, Amber Salter, PhD, Washington University School in St. Louis, St Louis, MO and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI - DMT51
Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
Mokshal H Porwal, BSc, Medical College of Wisconsin, Milwaukee, WI, Dhruvkumar Patel, BMSc, Arizona College of Osteopathic Medicine, Glendale, AZ, Michelle Maynard, PharmD, BCPS, Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI and Ahmed Z Obeidat, MD, PhD, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI - DMT52
Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans
Nicole Tsao, PhD, Shaobin Dong, MBA, Maria L Naylor, PhD, Qiang Hou, PhD and Mandakini Awasthy, MS, Biogen, Cambridge, MA - DMT53
Multiple Sclerosis Patients Initiating Ofatumumab in the Real-World: Early 3 Months Data
Patricia K. Coyle, MD1, Magdaliz Gorritz, MPH2, Rolin L Wade, RPh, MS2, Zifan Zhou, MS2, Yao Cao, MS2 and Chinmay Deshpande, PhD, BPharm3, (1)Department of Neurology, Stony Brook University, Stony Brook, NY, (2)IQVIA, Plymouth Meeting, PA, (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ - DMT54
Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study
Ralph H.B. Benedict, PhD1, Iris-Katharina Penner, PhD2, Ludwig Kappos, MD3, Patrick Vermersch, MD, PhD4, Bruce A.C. Cree, MD, PhD, MAS5, Ralf Gold, MD6, Amit Bar-Or, MD7, Daniela Piani-Meier, PhD8, Shannon Ritter, MS8, Sophie Arnould, MSc8, Goeril Karlsson, PhD8, Frank Dahlke, MD8, Thomas Hach, MD8, Robert J. Fox, MD9 and Douglas L. Arnold, MD10,11, (1)Jacobs Multiple Sclerosis Center, University at Buffalo, Buffalo, NY, (2)Medical Faculty, Department of Neurology, Heinrich Heine University, COGITO Center for Applied Neurocognition and Neuropsychological Research, Dusseldorf, Germany, (3)Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, (4)FHU Imminent, Univ. Lille, Inserm UMR U1172 LilNCog, CHU Lille, Lille, France, (5)UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, (6)Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, (7)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (8)Novartis Pharma AG, Basel, Switzerland, (9)Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH, (10)NeuroRx Research, Montreal, QC, Canada, (11)Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada - DMT55
Safety of Eculizumab in Nmosd and MG – Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions
Renato Mantegazza, MD1, Todd Levine, MD2, Celia Oreja-Guevara, MD3, Cynthia Carrillo-Infante, MD4, Eva Laudon-Meyer, MD PhD4, Shulian Shang, PhD4, Sean J Pittock, M.D.5 and James F. Howard Jr., MD6, (1)Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy, (2)Phoenix Neurological Associates, Phoenix, AZ, (3)Hospital Universitario Clinico San Carlos, Madrid, Spain, (4)Alexion Pharmaceuticals, Boston, MA, (5)Mayo Clinic, Rochester, MN, (6)Department of Neurology, University of North Carolina, Chapel Hill, NC - DMT56
Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years
Douglas L. Arnold, MD1,2, Ludwig Kappos, MD3, Patrick Vermersch, MD, PhD4, Ralf Gold, MD5, Amit Bar-Or, MD6, Gavin Giovannoni, MD, PhD7, Bruce A.C. Cree, MD, PhD, MAS8, Daniela Piani-Meier, PhD9, Shannon Ritter, MS10, Goeril Karlsson, PhD9, Frank Dahlke, MD9, Thomas Hach, MD9 and Robert J. Fox, MD11, (1)NeuroRx Research, Montreal, QC, Canada, (2)Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montreal, QC, Canada, (3)Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, (4)FHU Imminent, Univ. Lille, Inserm UMR U1172 LilNCog, CHU Lille, Lille, France, (5)Department of Neurology, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany, (6)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (7)Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, (8)UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, (9)Novartis Pharma AG, Basel, Switzerland, (10)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (11)Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH - DMT57
Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis
Robert T. Naismith, MD1, Jeffrey A Cohen, MD2, Amit Bar-Or, MD3, Giancarlo Comi, MD4, Krzysztof Selmaj, MD5, Hans-Peter Hartung, M.D.6, James K. Sheffield, MD, MBA, MS7, Neil Minton, MD FFPM7, Marc Gleichmann, MD7, Hongjuan Liu, MD7, Jon V Riolo, PhD7, Diego Silva, MD7 and Bruce A.C. Cree, MD, PhD, MAS8, (1)Washington University School of Medicine, St. Louis, MO, (2)Cleveland Clinic Mellen Center, Cleveland, OH, (3)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (4)University Vita-Salute San Raffaele, Milan, Italy, (5)Center for Neurology, Lodz, Poland, (6)Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine-University Düsseldorf, Dusseldorf, Germany, (7)Bristol Myers Squibb, Princeton, NJ, (8)UCSF Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA - DMT58
Is There ‘Wearing Off’ with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).
Rose-Marie M Jungquist, B.S.1, Martin Malik, B.S.2, Zoe Rimler, B.S.2, Elizabeth A Douglas, MPH1, Andrew J Bouley, M.D.1, Ellen S Lathi, M.D.1, Joshua D Katz, M.D.1 and Ilya Kister, MD3, (1)The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA, (2)Neurology, NYU Langone Health, New York, NY, (3)Multiple Sclerosis Comprehensive Care Center, Barnabas Health Medical Group, Livingston, NJ - DMT59
Acapella: B-Cell Repletion in Ocrelizumab-Treated Patients
Rosie M Jungquist, B.S., Elizabeth A Douglas, MPH, Andrew J Bouley, M.D., Ellen S Lathi, M.D. and Joshua D Katz, M.D., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA - DMT60
Clinical Outcomes in Patients with COVID-19 Infection during Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis
Radmila Karan, MD, Merck KGaA, Darmstadt, Germany, Darmstadt, Germany, Sanjeev Roy, MD, Merck KGaA, Darmstadt, Germany, Aubonne, Switzerland and Nektaria Alexandri, MD, MSc, Neurology and Immunology, Merck KGaA, Darmstadt, Germany, Darmstadt, Germany - DMT61
Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder
Sean J Pittock, M.D.1, Kazuo Fujihara, MD2,3,4, Jacqueline Palace, DM5, Achim Berthele, MD6, Ho Jin Kim, MD, PhD7, Celia Oreja-Guevara, MD8, Ichiro Nakashima, MD, PhD3,9, Michael Levy, MD, PhD10,11, Shulian Shang, PhD12, Marcus Yountz, MD12, Larisa Miller, PharmD12, Roisin Armstrong, PhD12 and Dean Wingerchuk, M.D.13, (1)Mayo Clinic, Rochester, MN, (2)Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, (3)Tohoku University, Sendai, Japan, (4)Fukushima Medical University, Fukushima City, Japan, (5)John Radcliffe Hospital, Oxford, United Kingdom, (6)Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany, (7)Research Institute and Hospital, National Cancer Center, Goyang, Korea, Republic of (South), (8)Hospital Universitario Clinico San Carlos, Madrid, Spain, (9)Tohoku Medical and Pharmaceutical University, Sendai, Japan, (10)Massachusetts General Hospital and Harvard Medical School, Boston, MA, (11)Johns Hopkins University, Baltimore, MD, (12)Alexion Pharmaceuticals, Boston, MA, (13)Mayo Clinic, Scottsdale, AZ - DMT62
Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis
Sibyl Wray, MD1, Marco Salvetti, MD2, Gereon Nelles, MD3, Arman Altincatal, MS4, Nydjie Grimes, MPH, BA4, Achint Kumar, MBBS, MD4 and Maria L Naylor, PhD4, (1)Hope Neurology MS Center, Knoxville, TN, (2)Sapienza University, S. Andrea Hospital, Rome, Italy, (3)Neurology, NeuroMed Campus Hohenlind, Cologne, Germany, (4)Biogen, Cambridge, MA - DMT63
Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the Asclepios I/II and Apolitos Studies
Silvia Delgado, MD1, Mitzi J Williams, MD2, Morten Bagger, PhD3, Gordon Graham, PhD3, Etienne Pigeolet, PhD3, Huixin Yu, PhD3, Dieter A. Haering, PhD3, Roman Willi, PhD3, Cecile Kerloeguen, MSc3, Chao Xu, PhD4, Masaru Hirano, PhD5, Dee Stoneman, MPharm3, Wendy Su, PhD6, Krishnan Ramanathan, PhD3 and Jin Nakahara, MD, PhD7, (1)Neurology, University of Miami Miller School of Medicine, Miami, FL, (2)Joi Life Wellness MS Center, Atlanta, GA, (3)Novartis Pharma AG, Basel, Switzerland, (4)China Novartis Institute of Biomedical Research, Shanghai, China, (5)Novartis Pharmaceutics, K.K., Tokyo, Japan, (6)Autoimmune, TG Therapeutics, Inc, New York, NY, (7)Department of Neurology, Keio University School of Medicine, Tokyo, Japan - DMT64
The Benefits of Azathioprine in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis
Smathorn Thakolwiboon, MD1, Hannah Zhao-Fleming, MD, PhD2, Amputch Karukote, MD1 and Mirla Avila, MD1, (1)Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, (2)Neurology, Mayo Clinic, Rochester, MN - DMT65
Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohn’s Disease
Sonia Afsari, MD1, Alyssa Henry, MD1, Giancarlo Comi, MD2, Marla C. Dubinsky, MD3, Uma Mahadevan, MD4, Lorna Charles, MD1, C. Janneke van der Woude, MD, PhD5 and Krzysztof Selmaj, MD6, (1)Bristol Myers Squibb, Princeton, NJ, (2)University Vita-Salute San Raffaele, Milan, Italy, (3)Icahn School of Medicine, Mount Sinai, NY, (4)University of California San Francisco, San Francisco, CA, (5)Erasmus MC, Rotterdam, Netherlands, (6)Center for Neurology, Lodz, Poland - DMT66
Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study
Stanley Cohan, MD, PhD1, Le H. Hua, MD2, Amit Bar-Or, MD3, Fred D. Lublin, MD4, Xiangyi Meng, PhD5, Gina Mavrikis Cox, PhD5, Patricia K. Coyle, MD6 and Robert J. Fox, MD7, (1)Providence Brain and Spine Institute, and Providence Multiple Sclerosis Center, Providence Health & Services, Portland, OR, (2)Lou Ruvo Center for Brain Health, Las Vegas, NV, (3)Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (4)Icahn School of Medicine at Mount Sinai, New York, NY, (5)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (6)Multiple Sclerosis Comprehensive Care Center, Stony Brook University, Stony Brook, NY, (7)Mellen Center for Treatment and Research in Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH - DMT67
A Single Center Retrospective Analysis of Insurance Policy Impact on the Choice of Multiple Sclerosis Disease Modifying Therapies
Stephanie L Reyes, BA, University of Michigan Medical School, Ann Arbor, MI and Andrew Romeo, MD, Neurology, University of Michigan, Ann Arbor, MI - DMT68
Online Medical Education Increases Knowledge Among Neurologists of Safety Considerations for Disease Modifying Therapies in Multiple Sclerosis
Thomas Finnegan, PhD1, Catherine Murray, MA1, John Maeglin, BA1 and Patricia K. Coyle, MD2, (1)Medscape Education, New York, NY, (2)Department of Neurology, Stony Brook University, Stony Brook, NY - DMT69
Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials
Gavin Giovannoni, MD, PhD, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, Aida Aydemir, MSc, EMD Serono Research & Development Institute Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Billerica, MA, Elisabetta Verdun di Cantogno, MD, PhD, Merck KGaA, Darmstadt, Germany, Thomas P. Leist, MD, Comprehensive Multiple Sclerosis Center, Division of Clinical Neuroimmunology, Jefferson University, Philadelphia, PA and CLASSIC-MS Steering Committee - DMT70
Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?
Tyler E Smith, M.D.1, Maya Madhavan, M.D.1, Daniel Gratch, M.D.1, Aneek Patel, B.S.2, Valerie Saha, NP1, Carrie Sammarco, DrNP1, Zoe Rimler, B.S.1, Guadalupe Zuniga, .1, Dunia Gragui, .1, Leigh E Charvet, PhD1, Gary Cutter, PhD3, Lauren Krupp, MD1, Ilya Kister, MD1 and Lana Zhovtis Ryerson, M.D.1, (1)Neurology, NYU Langone Health, New York, NY, (2)NYU School of Medicine, New York, NY, (3)University of Alabama at Birmingham, Birmingham, AL - DMT71
Comparison of Therapy Selection Drivers within the S1P Receptor Modulator and Fumarate Classes Among Multiple Sclerosis Patients Who Recently Switched Treatment
Virginia R. Schobel, MSc, Spherix Global Insights, Exton, PA - DMT72
Therapy Selection Considerations during the COVID-19 Pandemic Among Patients with Progressive Multiple Sclerosis: Analyses from Retrospective Patient Chart Audit
Virginia R. Schobel, MSc, Spherix Global Insights, Exton, PA - DMT73
Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study
Xavier Montalban, MD, PhD1, Douglas L. Arnold, MD2, Martin S Weber, MD3, Ivan Staikov, MD, PhD4, Karolina Piasecka-Stryczynska, PhD5, Emily C. Martin, PhD6, Matthew Mandel, MD7, Yulia Zima, PhD6, Jamie Shaw, BS6, Fernando Dangond, MD, MBA6, Roland Grenningloh, MD6, Ying Li, MS8, Davorka Tomic, DVm, MSc, PhD9 and Jerry S Wolinsky, MD10, (1)Vall d’Hebron University Hospital, Barcelona, Spain, (2)McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital, McGill University, Montreal, QC, Canada, (3)Neurologie & Neuropathologie, Universitie Göttingen, Göttingen, Germany, (4)Department of Neurology, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria, (5)Department of Neurology and Cerebrovascular Diseases, Poznan University of Medical Sciences, Poznan, Poland, (6)EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, Rockland, MA, (7)EMD Serono Research & Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt, Germany), Billerica, MA, (8)EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Global Clinical Development Center, Billerica, MA, (9)Merck KGaA, Darmstadt, Germany, (10)McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX - DMT74
Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis
Tarun Singhal, MD1, Kelsey Carter, BS1, John Hunter Ficke, BA1, Preksha Kukreja, BS1, Eero Rissanen, MD, PhD1, Gauruv Bose, MD1, Bonnie Glanz, PhD1, Jonathan Zurawski, MD1, Steven Cicero, BS1, Maria Houtchens, MD1, Christopher A Severson, MD1, Shipra Dubey, PhD2, Bo Yeun Yang, PhD2, Brandon Brown, PharmD3, Rohit Bakshi, MD1, Harald Kropshofer, PhD4, Tanuja Chitnis, MD1, Howard L Weiner, MD1 and Marina Ziehn, PhD4, (1)Brigham Multiple Sclerosis Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, (2)Nuclear Medicine Division, Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, (3)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (4)Novartis Pharma AG, Basel, Switzerland - DMT75
Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls
Timothy Vollmer, MD1, Daniel Pelletier, MD2, Sibyl Wray, MD3, Barry Hendin, MD4, Linda-Ali Cruz, MD5, James Stankiewicz, MD5, Ratnakar Pingili, MBBS5, Xiangyi Meng, PhD5, Andy Cheadle, PhD5 and Jeffrey A Cohen, MD6, (1)Rocky Mountain MS Center, Aurora, CO, (2)Multiple Sclerosis Comprehensive Care Center At USC, Los Angeles, CA, (3)Hope Neurology, Knoxville, TN, (4)Center for Neurology and Spine, Phoenix, AZ, (5)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (6)Cleveland Clinic Mellen Center, Cleveland, OH
Epidemiology and Genetics
EPI01 Demographic and Clinical Associations with Neuromyelitis Optica Spectrum Disorder in an Academic Medical Center Clara Wan, BA1, Stacey S Cofield, PhD2, Kendall Curtis, BS1, William R Meador, MD3 and John R Rinker, MD4, (1)University of Alabama at Birmingham, Birmingham, AL, (2)Biostatistics, University of Alabama at Birmingham, Birmingham, AL, (3)Neurology, Birmingham VA Medical Center, Birmingham, AL, (4)Neurology, University of Alabama at Birmingham, Birmingham, AL
EPI02 Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry Daniel Kantor, MD1, Bruce Bebo, PhD2, Peter Wahl, MLA, MS, ScD3, Patricia K. Coyle, MD4, Edward J Fox, MD, PhD5, Robert A Bermel, MD6, Jon V Riolo, PhD7, Diego Silva, MD7, Christina Wright, PharmD7, Wendi Malley, MPH3, Jud C Janak, PhD, MPH3 and Aaron E Miller, MD8, (1)Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, (2)National Multiple Sclerosis Society, New York, NY, (3)Corrona, LLC, Waltham, MA, (4)Department of Neurology, Stony Brook University, Stony Brook, NY, (5)Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas, Round Rock, TX, (6)Department of Neurology, Cleveland Clinic Foundation, Cleveland, OH, (7)Bristol Myers Squibb, Princeton, NJ, (8)Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, NY
EPI03 Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) Kottil Rammohan, MD1, David Li, MD, FRCPC2, June Halper, MSN, APN-C, MSCN, FAAN3, Sara McCurdy Murphy, BA4, Lisa Patton, BA4, Chao Zheng, MD5 and Seema Khurana, DO5, (1)Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL, (2)Radiology and Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (3)Consortium of Multiple Sclerosis Centers, Hackensack, NJ, (4)Social & Scientific Systems, Silver Spring, MD, (5)University of Miami, Miami, FL
EPI04 Population-Based Incidence and Clinico-Radiological Characteristics of Tumefactive Multiple Sclerosis in Olmsted County, Minnesota, USA Mahboobeh Fereidan-Esfahani, M.D.1, Paul Decker, M.S.2, Jeanette Eckel Passow, PhD2 and Oliver Tobin, M.B. B.Ch. B.A.O. Ph.D.1, (1)Neurology, Mayo Clinic, Rochester, MN, (2)Health Sciences, Mayo Clinic, Rochester, MN
Family and Caregivers
- FAM01
Evidence of Distress By Multiple Sclerosis (MS) Patient Caregiver As a Consequence of COVID-19
Casey K Gilman, BS1, Paulina Díaz de la Matta, MA2, Evián Pérez Rivera, BS1, Ramón Vega Corteguera, BS3, Ivonne Vicente Loperena, MD3, Viviana Martinez Maldonado, BS3 and Angel Chinea, MD4, (1)San Juan Bautista School of Medicine, Caguas, PR, (2)Universidad Central del Caribe, Bayamón, PR, (3)San Juan Multiple Sclerosis Center, Guaynabo, PR, (4)San Juan MS Center, Guaynabo, PR, Puerto Rico - FAM02
Parents’ Experiences of a Multiple Sclerosis (MS) Diagnosis in Their Young Adult Sons/Daughters: An Interpretative Phenomenological Study
Ciara M O’Meara, MHSc, M.A.T., BSc, RNT, RGN, Clinical Research Facility, University of Ireland Galway, Galway, Ireland - FAM03
Caregiving Challenges in Multiple Sclerosis and Alzheimer’s Disease: Results from a Caregiver Survey Study in Two Virtual Communities
Hollie Schmidt, MS1, Sara Loud, MSEE, MBA1, Theresa Frangiosa, MBA2, Virginia Biggar, BA2, Jason Resendez, BA2 and Stephanie Monroe, JD3, (1)Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, (2)UsAgainstAlzheimer’s, Washington, DC, (3)African Americans Against Alzheimer’s, Washington, DC - FAM04
Profiles of Resilience Among MS Care Partners
Katherine L. Cardwell, BHSc1, Odessa McKenna, BSc1, Afolasade Fakolade, PhD2, Lara A. Pilutti, PhD1 and Jason Steffener, PhD3, (1)Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada, (2)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, (3)School of Interdisciplinary Health Sciences, University of Ottawa, Ottawa, ON, Canada
Internet and Information Services
- IIS01
Using a University Canvas Learning Management System to Increase Knowledge about MS: The Multiple Sclerosis Student Advocates Program As an Educational Intervention
A. Suzanne Boyd, PhD, MSW, School of Social Work, The University of North Carolina at Charlotte, Charlotte, NC and Shelby Veri, MPH, CHES, CPH, Department of Public Health Sciences, University of North Carolina at Charlotte, Charlotte, NC - IIS02
MS and COVID-19: A Webinar Series for Healthcare Providers
Doris Lill, BS, PMP Director Healthcare Access, Advocacy, Services and Research, National Multiple Sclerosis Society, Denver, CO, Kathleen Costello, MS, ANP-BC, MSCN, Can Do MS, Avon, CO, Julie Fiol, MSW, BSN, RN, MSCN, National MS Society, Bel Aire, MD and June Halper, MSN, APN-C, MSCN, FAAN, Consortium of Multiple Sclerosis Centers, Hackensack, NJ - IIS03
Passive Monitoring of Cognition Using a Smartphone Application in MS
Michelle H Chen, PhD1, Mindy Ross, BS2, John DeLuca, PhD1 and Alex Leow, MD/PhD2, (1)Kessler Foundation, East Hanover, NJ, (2)University of Illinois at Chicago, Chicago, IL - IIS04
Use of an Infographic for Individualized Patient Discharge Instruction in the Spinal Cord Injured and Disorders Population
Tomicka S McMillion, RN, DNP, MSCN, SPINAL CORD INJURY AND DISORDERS, VANJHCS, EAST ORANGE, NJ and CMSC Author’s Group
Imaging
- IMG07
First Steps Towards Implementation of a Standardized MRI Protocol to Improve Care for People with MS in British Columbia
David KB Li, MD FRCPC1, Hae Jung Min, BA2, Samuel Yim, MHA3, Adelia Adelia, MSc4, Shelly Au, PhD4, Jason Shewchuk, MD, FRCPC5, Laura Barlow, RTR, RMTR6, Laura Harvey, BA4, Shannon Kolind, PhD4, Roger Tam, PhD7, Bruce Forster, MSc MD FRCPC FCAR5, Monty Martin, MD FRCPC5, Carolyn Rudden, BSc MA8, Lori Saslow, MS9, June Halper, MSN, APN-C, MSCN, FAAN9 and Anthony Traboulsee, MD, FRCPC4, (1)Radiology and Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (2)University of British Columbia, Vancouver, BC, Canada, (3)Vancouver Coastal Health, Vancouver, BC, Canada, (4)Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (5)Radiology, University of British Columbia, Vancouver, BC, Canada, (6)UBC MRI Research Centre, Vancouver, BC, Canada, (7)Radiology & School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada, (8)British Columbia Ministry of Health, Victoria, BC, Canada, (9)Consortium of Multiple Sclerosis Centers, Hackensack, NJ - IMG08
Could Cerebral Autoregulatory Collapse Explain Cognitive Impairment in MS?
Dinesh K Sivakolundu, MD, PhD1,2, Mark D Zuppichini, MA3, Kathryn West, PhD4, Gayathri B Maruthy, MS5, Monroe Turner, PhD5, Dema Abdelkarim, BS5, Yuguang Zhao, MS5, Peter Herman, PhD6, Stephan Kaczmarz, PhD7, Fahmeed Hyder, PhD6, Robert Fulbright, MD6, Erin E Longbrake, MD, PhD1, Darin T Okuda, MD8 and Bart Rypma, PhD9, (1)Neurology, Yale University, New Haven, CT, (2)Biological Sciences, University of Texas at Dallas, Dallas, TX, (3)School of Behavioral and Brain Sciences, University of Texas At Dallas, Richardson, TX, (4)Center for BrainHealth, Dallas, TX, (5)University of Texas at Dallas, Dallas, TX, (6)Yale University, New Haven, CT, (7)Technical University of Munich School of Medicine, Munich, Germany, (8)UT Southwestern Medical Center, Dallas, TX, (9)School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, TX - IMG09
Neural Correlates of Hand Motor Function Revealed By Structural MR Imaging: A Smartphone-Based Remote Assessment Study in People with MS
Marco Ganzetti, PhD1, Sven Holm, PhD1, Frank Dondelinger, PhD1, Jennifer Graves, MD PhD MAS2,3, Luciana Midaglia, MD4,5, Laura Gaetano, PhD1, Licinio Craveiro, MD, MSc, PhD1, Florian Lipsmeier, PhD1, Corrado Bernasconi, MD, PhD1, Xavier Montalban, MD, PhD, MBA4, Stephen L. Hauser, MD3 and Michael Lindemann, MD, PhD1, (1)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (2)Department of Neurology, University of California San Diego, San Diego, CA, (3)Department of Neurology, University of California San Francisco, San Francisco, CA, (4)Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, (5)Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain - IMG10
Prefrontal Metabolism Is Associated with Processing Speed in Multiple Sclerosis: A Calibrated fMRI Study
Mark D Zuppichini, MA, School of Behavioral and Brain Sciences, University of Texas At Dallas, Richardson, TX, Dinesh Sivakolundu, MD, Department of Neurology, Yale School of Medicine, New Haven, CT, Kathryn West, PhD, Center for BrainHealth, Dallas, TX, Darin T Okuda, MD, UT Southwestern Medical Center, Dallas, TX and Bart Rypma, PhD, School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, TX - IMG11
Importance of Cervical Magnetic Resonance Imaging in the Diagnosis, Treatment, and Monitoring of Hispanic Puerto Rican Multiple Sclerosis Patients
Ramon J. Vega-Corteguera, BS1, Jean P. Godreau, MD2, Viviana Martinez-Maldonado, BS1, Paulina Díaz de la Matta, MA3, John K. Pendas, BS4, Ivonne Vicente-Loperena, MD1 and Angel R. Chinea-Martinez, MD5, (1)Clinical Research, San Juan MS Center, Guaynabo, PR, (2)Universidad Central del Caribe, Bayamon, PR, (3)Universidad Central del Caribe, Bayamón, PR, (4)Escuela de Medicina San Juan Bautista, Caguas, PR, (5)San Juan MS Center, Guaynabo, PR - IMG12
Compliance of a Real-World Dataset with the CMSC 2018 Guidelines
Sophie Vercruyssen, MSc1, Shannon Kolind, PhD2, Shelly Au, PhD2, Adelia Adelia, MSc2, Diana M Sima, PhD1, Dirk Smeets, PhD3, David Li, MD, FRCPC4 and Anthony Traboulsee, MD, FRCPC2, (1)R&D, icometrix, Leuven, Belgium, (2)Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (3)icometrix, Leuven, Belgium, (4)Radiology and Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada - IMG13
Influence of Imaging Parameters on MRI Contrast Using Qualitymetrix Sophie Vercruyssen, MSc1, Shannon Kolind, PhD2, Shelly Au, PhD2, Adelia Adelia, MSc2, Diana M Sima, PhD1, Dirk Smeets, PhD3, Anthony Traboulsee, MD, FRCPC2 and David Li, MD, FRCPC4, (1)R&D, icometrix, Leuven, Belgium, (2)Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada, (3)icometrix, Leuven, Belgium, (4)Radiology and Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada - IMG14
Relationship of Functional Outcomes and Routinely Performed MRI Studies in Persons with Multiple Sclerosis: An Insight into the Frontal Lobe Structural Alterations
Zaenab Dhari, MD1,2, Steven Kracke, MSc3, Marco Pisa, MD4, Gabriele C DeLuca, MD, DPhil4, Albert C. Lo, MD, PhD5, Heather M DelMastro, MSc1,2, Mary Bailey, MD1,2 and Jennifer Ruiz, DPT1,2, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (2)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (3)Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, USA, North Haven, CT, (4)Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom, (5)Departments of Neurology and Engineering, Brown University, Providence, RI - IMG15
Trajectories of the Frontal Lobe Structural Changes in Relation to Retrospective and Prospective Memory in Persons with Multiple Sclerosis
Zaenab Dhari, MD1,2, Jennifer Ruiz, DPT1,2, Lindsay O Neto, MPH1,2, Marco Pisa, MD3, Gabriele C DeLuca, MD, DPhil3, Mary Bailey, MD1,2 and Elizabeth S Gromisch, PhD1,2,4, (1)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (2)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (3)Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom, (4)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT - IMG16
Functional Neuroimaging Metrics Predict Processing Speed and Correlate with Disease Burden in Relapsing-Remitting Multiple Sclerosis
Anita Shankar, M.S., Heena R. Manglani, M.A., Oyetunde Gbadeyan, Ph.D. and Ruchika S. Prakash, Ph.D., Department of Psychology, The Ohio State University, Columbus, OH
Multidisciplinary Care
- MDC01
Religiosity and Mental Health in Multiple Sclerosis
Alice E Dias, Dr, Scientific Research, Brazilian Multiple Sclerose Association (ABEM), São Paulo, Brazil, Gina Corsi, MSc, Occupational Therapy, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil and Mauricio O Bando, Neuropsychologist, Neurorehabilitation, ABEM – Brazilian Multiple Sclerosis Association, Sao Paulo, Brazil - MDC02
Study about Depression and Attention Performance in People with Multiple Sclerosis
Mauricio O Bando, Neuropsychologist, Neurorehabilitation, ABEM – Brazilian Multiple Sclerosis Association, Sao Paulo, Brazil, Alice E Dias, Dr, Scientific Research, Brazilian Multiple Sclerosis Association (ABEM), Sao Paulo, Brazil, Ana M Canzonieri, Dr, Psychology, Brazilian Multiple Sclerosis Association (ABEM), Sao Paulo, Brazil, Talita D Silva, Dr, Sao Paulo University, Sao Paulo, Brazil and Marcelo Massa, Doctor, EACH, USP – Sao Paulo University, Sao Paulo, Brazil - MDC03
Brazilian Case of Telerehabilitation in Multiple Sclerosis in the Pandemic Period By COVID-19
Alice E Dias, Dr1, Guilherme Olival Sr., doctor2, Juliana AR Telles, MSc3, Mauricio O Bando, Neuropsychologist4, Antonio Y Chiarella, Dr5, Camila Carvalho, Dr5, Camilo Lobo, psychologist6, Priscila S Santos, Social Worker7, Gisele R Barboza, Social Worker7, Roseli Minervino, Therapist8, Teresa K Teng, Ms8, Margareth MT Zampieri, Ms8, Danielle Souza, Social Worker7, Bruna H Sciarinni, Physiotherapist3 and Gecila F Aragão, Social Worker7, (1)Scientific Research, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (2)neurologia, santa casa de misericórdia de são paulo, São Paulo, Brazil, (3)Physiotherapy, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (4)Neurorehabilitation, ABEM – Brazilian Multiple Sclerosis Association, Sao Paulo, Brazil, (5)Neurology, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (6)Psychology, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (7)Social Service, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil, (8)Alternative / complementary therapies, Brazilian Multiple Sclerose Association (ABEM), Sao Paulo, Brazil - MDC04
Health Resource Utilization Among Individuals with Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)
Aman Saini, MD, MPH1, Ilia Poliakov, BHSc (Hon), MD, FRCPC2, Katherine B. Knox, MD, FRCPC3, Chantal Kahovec, RN(NP)4, Shirley MacGowan, RN, MSCN5, Candace Lahoda, RN4, Colleen Cochran, BA (Hons.)1 and Michael C. Levin, MD, FRCPC, FAAN, FANA6, (1)Office of the Saskatchewan MS Clinical Research Chair, University of Saskatchewan, Saskatoon, SK, Canada, (2)Department of Neurology, University of Saskatchewan, Saskatoon, SK, Canada, (3)Department of Physical Medicine and Rehabilitation, University of Saskatchewan, Saskatoon, SK, Canada, (4)Saskatoon MS Clinic, Saskatchewan Health Authority, Saskatoon, SK, Canada, (5)Saskatchewan MS Drugs Program, Department of Physical Medicine and Rehabilitation, University of Saskatchewan, Saskatoon, SK, Canada, (6)Department of Neurology and Department of Anatomy, Physiology & Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada - MDC05
National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis
Annette F Okai, MD1, Annette M Howard, MD2, Mitzi J Williams, MD3, Justine D Brink, DO, MPH4, Chiayi Chen, RN, PhD4, Tamela L Stuchiner, MA4, Elizabeth Baraban, MPH, PhD4 and Stanley Cohan, MD, PhD5, (1)Multiple Sclerosis Treatment Center of Dallas, Dallas, TX, (2)Multiple Sclerosis Institute of Texas, Houston, TX, (3)Joi Life Wellness MS Center, Atlanta, GA, (4)Providence Brain and Spine Institute, Portland, OR, (5)Providence Multiple Sclerosis Center, Providence Brain Institute, Portland, OR - MDC06
Holy Name MS Center Covid-19 Vaccine Distribution Experience
Asya I. Wallach, MD, Matthew Schiebel, RN, Christal Radburn, RMA, MSHA, Reena Mathew, RN, Dana Jones, NP and Mary Ann Picone, MD, Holy Name Medical Center, Teaneck, NJ - MDC07
Diving into Complex Durable Medical Equipment Needs: The Multiple Sclerosis at Home Access Program (MAHA)
Aubrie L Lindner, AA1, Renee Stewart, DNP, APRN-NP2, Kristen Bayly, BSN2, Rana K. Zabad, MD3, Joey Rubenthaler, ATP4, Nathan Reitz, ATP5, Scott Richotte, BS6, Mohamed Darwish, MD7, Kathleen Healey, NP, PhD8 and CMSC Clinical MAHA team and CRT team, (1)Neurological Sciences Program Operations Manager, Nebraska Medicine, Omaha, NE, (2)Neurological Sciences, Nebraska Medicine, Omaha, NE, (3)Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, (4)ATP, Numotion, Omaha, NE, (5)Director of Sales Operations, Numotion, Lincoln, NE, (6)VP of Sales and Clinical Relations, Numotion, Lincoln, NE, (7)Department of Neurology, University Nebraska Medical Center, Omaha, NE, (8)Neurologial Sciences, University of Nebraska, Omaha, NE - MDC08
Promising Opportunities to Integrate Health and Wellness Coaching into Comprehensive Care Teams for Patients with Multiple Sclerosis
Janean W Jenkins, MSN, APRN, CNRN, CNS, NBC-HWC, Multiple Sclerosis Makeover, San Antonio, TX - MDC09
The Treatment with Physiotherapy and Pilates and the Impact on Functionality and Quality of Life of Patients with Recurrent Relapsing Multiple Sclerosis
Juliana Rhein1, Irana Souza Castro, IRANA2, Edson Toshiro Nakau, edson3, Rita H Labronici, Rita2 and Alice E Dias, Doctor4, (1)Rehabilitation, Associação Brasileira de Esclerose Múltipla, São Paulo/SP, Brazil, (2)Physical Therapy, Faculdade De Medicina DO ABC, São PAULO, Brazil, (3)Physical Therapy, Faculdade De Medicina DO ABC, São Paulo, Brazil, (4)Neurorehabilitation, ABEM – Brazilian Multiple Sclerosis Association, Sao Paulo, Brazil - MDC10
Integrated Clinic-Based Pharmacist Impact on Time to Fingolimod Treatment Initiation
Lisa Aquillano, PharmD, BCPS, MSCS, Neil Lava, MD and Calli Cook, DNP, FNP-C, FAANP, Neurology, The Emory Clinic, Atlanta, GA - MDC11
Association between Patient Reported Outcomes and Gait in People with Multiple Sclerosis with Differing Disabilities
Christina Burke, PT, DPT1,2, Olivia Kaczmarek, BS3, MaryJo Kaleda, PT, DPT1, Elizabeth Casparian, SPT1, James Forbes, SPT1, Jillian Gallindo, SPT1, Morgan Staten, SPT1, Jared Srinivasan, BA3 and Mark Gudesblatt, MD4, (1)Stony Brook University, Stony Brook, NY, (2)South Shore Neurologic Associates, P.C., Patchogue, NY, (3)South Shore Neurologic Associates, Patchogue, NY, (4)South Shore Neurologic Associates, P.C., Islip, NY
Methods of Care
- MOC01
Impact of the COVID-19 Pandemic on People with Multiple Sclerosis: Results from an International Survey
Alana T Wong, PhD1, Svend S Geertsen, PhD1, Hubert van Hoogstraten, MD, PhD2, Bill Aschenbach, PhD, MBA1 and Jeffrey Chavin, MD, FAAN1, (1)Sanofi, Cambridge, MA, (2)Sanofi, Bridgewater, NJ - MOC02
Psychoanalytic Telepsychology with MS Patients and Their Support People
Gayle R Lewis, Ph.D., MSCS, New York, NY - MOC03
Floodlight MS: Using the Jobs-to-be-Done Framework to Identify Unmet Needs in Multiple Sclerosis Care to Support Digital Medical Device Development
Jorge Cancela, PhD, MBA, Roche, Basel, Switzerland, Cristina Costantino, PhD, Genentech, South San Francisco, CA and Jumaah Goldberg, DPT, Genentech, Inc., South San Francisco, CA - MOC04
Floodlight MS: Utilizing Rapid Prototyping and Human Factors Studies to Develop a Digital Medical Device for Patient-Centric MS Care
Jorge Cancela, PhD, MBA1, Cristina Costantino, PhD2, Jumaah Goldberg, DPT3, Geraint Davies, BSc1 and JP Guyon, MS, MBA4, (1)Roche, Basel, Switzerland, (2)Genentech, South San Francisco, CA, (3)Genentech, Inc., South San Francisco, CA, (4)Roche, Belmont, CA - MOC05
Improving Communication Gaps between Physicians Who Treat MS and the Health Insurance Community
Alexis Crispino, Director of Education & Healthcare Relations (MSAA South-Central), Multiple Sclerosis Association of America, Austin, TX and Kyle E Pinion, Senior Director of Education, Healthcare Relations & Advocacy, Education and Healthcare Relations, Multiple Sclerosis Association of America, Cherry Hill, NJ - MOC06
Remote Monitoring in MS – Initial Experience with Medical Device ICompanion
Lars Costers, PhD1,2, Annabel Descamps, MSc1, Steve De Backer, PhD1, Guy Nagels, MD PhD1,2,3,4, Wim Van Hecke, PhD1 and Dirk Smeets, PhD1,2, (1)icometrix, Leuven, Belgium, (2)AIMS, Vrije Universiteit Brussel (VUB), Brussel, Belgium, (3)Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussel, Belgium, (4)St. Edmund Hall, University of Oxford, Oxford, United Kingdom - MOC07
Development and Implementation of a Psychoeducational Model for a Pediatric MS Clinic Transition Program
Yolanda S Wheeler, PhD, CRNP, CPNP-AC, MSCN, University of Alabama at Birmingham Center for Pediatric Onset Demyelinating Disease, Birmingham, AL; University of Alabama at Birmingham School of Nursing, Birmingham, AL and Evelyn Hunter, PhD, Department of Special Education, Rehabilitation and Counseling, Auburn University, Auburn, AL
Neuroimmunology and Disease Models
- NDM01
Clinical and Diagnostic Spectrum of Optic Neuritis: A Single-Center Retrospective Study of Disorders Associated with Multiple Sclerosis, Aquaporin-4 Antibody, and Myelin Oligodendrocyte Glycoprotein Antibody
Dana Siegel, MD, Wayne State University, School of Medicine, Detroit, MI, Meredith Van Harn, MPH, Neurology, Henry Ford Health System, Detroit, MI, Poonam Bansal, MD, Ophthalmology and Neurology, Henry Ford Health System, Detroit, MI, Mirela Cerghet, MD, PhD, Neurology, Henry Ford Hospital, Detroit, MI and Anza B Memon, MD, Neurology, Henry Ford Health System, Detroit, MI; Neurology, Wayne State University, School of Medicine, Detroit, MI - NDM02
RGC-32 Contributes to Reactive Astrocytosis in Experimental Autoimmune Encephalomyelitis By Maintaining a Mature Phenotype
Austin J Beltrand, Medical Student, University of Maryland SOM, Baltimore, MD, Horea Rus, MD, PhD, Veterans Administration Multiple Sclerosis Center of Excellence, Baltimore, MD and Alexandru Tatomir, MD, Neurology, University of Maryland SOM, Baltimore, MD - NDM03
Comparing Infection-Related Outcomes By Sex in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data
Riley Bove, MD1, Terra Slaton, MS2, Chris M. Kozma, PhD2, Amy L. Phillips, PharmD3, Danielle E. Harlow, PhD3 and Carroline Lobo, PhD3, (1)UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, (2)CK Consulting Associates, LLC, West Columbia, SC, (3)EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany - NDM04
Effect of Ocrelizumab on Antibody Responses to EBV
Kaleigh E Olmsted, B.S., McGovern Medical School, Houston, TX and John W Lindsey, MD, Multiple Sclerosis And Neuroimmunology, McGovern Medical School, Houston, TX - NDM05
Mucosal Associated Invariant T (MAIT) Cells Show Defective Activation in People with Multiple Sclerosis
Laura Ghezzi, MD1,2, Claudia Cantoni, PhD3, Daniela Galimberti, PhD2, Elio Scarpini, MD2, Anne Cross, MD1 and Laura Piccio, M.D., Ph.D1,4, (1)Neurology, Washington University in St. Louis, St. Louis, MO, (2)University of Milan, Milan, Italy, (3)Neurology, Washington University in St. Louis, St. louis, MO, (4)Brain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia - NDM06
Phenotype and Functional Characterization of B-Cells, T-Cells and Monocytes Following Alemtuzumab Treatment in Patients with Multiple Sclerosis.
Nicole Kashani, M.D., Borna Vajdi, M.D., Lauren M Anderson, B.S., Gregory Baltayan, B.S., Eve E Kelland, Ph.D., Wendy Gilmore, Ph.D. and Brett T Lund, Ph.D., Neurology, University of Southern California, Los Angeles, CA - NDM07
Enhanced IL2 Induced Activation of STAT5 in Effector CD4 and CD8 T Cell Populations from Treatment Naïve Relapsing Multiple Sclerosis
William Meador, MD, Neurology, UAB, Birmingham, AL and Chander Raman, PhD, Medicine, University of Alabama at Birmingham, Birmingham, AL
Non-imaging Biomarkers
- NIB01
The Effect of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis
Jens Kuhle, MD, PhD1, Ludwig Kappos, MD2, Xavier Montalban, MD, PhD3, Ying Li, MS4, Karthinathan Thangavelu, PhD4, Yann Hyvert, PhD5 and Davorka Tomic, PhD5, (1)Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, and University of Basel, Basel, Switzerland, (2)Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Medicine, Clinical Research and Biomedical Engineering, University Hospital Basel, and University of Basel, Basel, Switzerland, (3)Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain, (4)EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Global Clinical Development Center, Billerica, MA, (5)Merck KGaA, Darmstadt, Germany - NIB02
Concentration of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, in Cerebrospinal Fluid during Treatment of Patients with Relapsing Multiple Sclerosis in a Phase 2 Study
Karolina Piasecka-Stryczynska, PhD1, Konrad Rejdak, MD, PhD2, Martin Dyroff, PhD3, Yann Hyvert, PhD4, Kristina Holmberg, PhD3, Matthew Mandel, MD3, Carolina Cunha, PhD, PharmD3, David Mitchell, PhD5, Emily C. Martin, PhD3 and Xavier Montalban, MD, PhD6, (1)Department of Neurology and Cerebrovascular Diseases, Poznan University of Medical Sciences, Poznan, Poland, (2)Department of Neurology, Medical University of Lublin, Lublin, Poland, (3)EMD Serono Research & Development Institute, Inc (an affiliate of Merck KGaA, Darmstadt, Germany), Billerica, MA, (4)Merck KGaA, Darmstadt, Germany, (5)Nuventra Inc., Broomfield, CO, (6)Department of Neurology-Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain - NIB03
Combinatorial Analysis of Plasma and DNA Methylation Biomarkers in African American Patients with Multiple Sclerosis
Lindsay Clark, PhD1, Mark Band, PhD2, Jason P. Mendoza, PhD3, Linda Piccinini, PhD3 and Michael D Carrithers, MD, PhD4,5,6, (1)High Performance Biological Computing, Roy J. Carver Biotechnology Center, University of Illinois, Urbana, IL, (2)Functional Genomics, Roy J. Carver Biotechnology Center, University of Illinois, Urbana, IL, (3)Biogen, Cambridge, MA, (4)Neurology, University of Illinois College of Medicine, CHICAGO, IL, (5)Neurology, Jesse Brown Veterans Hospital, Chicago, IL, (6)Physiology and Biophysics, University of Illinois College of Medicine, Chicago, IL - NIB04
Predicting Stress Levels and Response to a Self-Management Program Using Participant Demographic, Clinical, and Biomarker Data: A Secondary Analysis
Nico Osier, PhD, RN1,2, Alexa Stuifbergen, PhD, RN, FAAN1, Sawyer Stubbs, BS3 and Tapasvini Paralkar, BS3, (1)School of Nursing, The University of Texas at Austin, Austin, TX, (2)Neurology, Dell Medical School, Austin, TX, (3)University of Texas at Austin, Austin, TX - NIB05
Non-Right-Handedness May be Associated with More Severe Multiple Sclerosis
Ruth E Propper, Ph.D.1, Melissa Villafana, B.A.1 and Glenn R Wylie, Ph.D.2, (1)Psychology, Montclair State University, Montclair, NJ, (2)Rocco Ortenzio Neuroimaging Center, Kessler Foundation, West Orange, NJ - NIB06
Validating the Clinical Usefulness of the Timed 25-Foot Walk in MS in Routine Clinical Practice
Sage T Hewitt, B.S.1, Derrick Robertson, MD2, Angela Aungst, MPH3 and Christopher James, B.S.1, (1)USF Health Morsani College of Medicine, Tampa, FL, (2)College of Medicine, Neurology, University of South Florida, Tampa, FL, (3)Multiple Sclerosis Division Department of Neurology University of South Florida, Florida, FL - NIB07
Cerebrospinal Fluid Protein Is Higher in Males with Multiple Sclerosis: Results from an International Multicenter Cohort
Sam I Hooshmand, DO1, Khalid El-Salem, MD2, Suha Agaileh, MD2 and Ahmed Z Obeidat, MD, PhD1, (1)Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, (2)Department of Neurosciences, Jordan University of Science and Technology, Irbid, Jordan
Neurophysiology; Neuropsychology and Neuropsychiatry
- NNN01
Identifying Prospective Memory Deficits in MS with a Single Task from the Memory for Intentions Test: An IRT and ROC Analysis
Elizabeth S Gromisch, PhD1,2,3, Aaron P Turner, Ph.D. ABPP (RP)4,5,6, Lindsay O Neto, MPH1,7 and Sarah A Raskin, PhD8,9, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (2)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT, (3)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (4)Department of Rehabilitation Medicine, University of Washington, Seattle, WA, (5)Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, WA, (6)Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, WA, (7)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (8)Neuroscience Program, Trinity College, Hartford, CT, (9)Department of Psychology, Trinity College, Hartford, CT - NNN02
Stability of the Gut Microbiota in Persons with Pediatric-Onset Multiple Sclerosis and Related Demyelinating Diseases
Geoffrey Liang, BSc1, Feng Zhu, MSc2, Ali Mirza, MSc2, Douglas L. Arnold, MD3, Amit Bar-Or, MD, FRCPC4, Charles Bernstein, MD5, Jessica Forbes, PhD6, Janace Hart, BA7, Ruth A Marrie, PhD8, Julia O’Mahony, PhD5, E Ann Yeh, MD9, Yinshan Zhao, Ph.D.2, Brenda Banwell, MD10, Emmanuelle Waubant, MD PhD11, Helen Tremlett, PhD12 and on behalf of the Gut microbiota in Pediatric-onset MS study team and the Canadian Pediatric Demyelinating Disease Network, (1)Medicine, University of British Columbia, Vancouver, BC, Canada, (2)Neurology, University of British Columbia, Vancouver, BC, Canada, (3)McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital, McGill University, Montreal, QC, Canada, (4)Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (5)University of Manitoba, Winnipeg, MB, Canada, (6)Laboratory Medicine & Pathobiology,, University of Toronto, Toronto, ON, Canada, (7)UCSF Pediatric MS Center, San Francisco, CA, (8)Department of Internal Medicine (Neurology), University of Manitoba, Winnipeg, MB, Canada, (9)Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, Toronto, ON, Canada, (10)Neurology, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (11)Neurology, University of California San Francisco, San Francisco, CA, (12)Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada - NNN03
Evaluation of Apathy in Multiple Sclerosis
Jeannie Lengenfelder, PhD1, Helen Genova, PhD1, Jacqueline Leddy, BA1, Brea Rivera, BS2 and Nancy D Chiaravalloti, PhD1, (1)Kessler Foundation, East Hanover, NJ, (2)Montclair State University, Montclair, NJ - NNN04
FlywheelMS: Stratification of Anxiety and Depression By MS Subtype As Captured in Digitized Health Records
Kelly Zalocusky, PhD1, Ryan Gan, PhD, MPH1, Shemra Rizzo, PhD1, Katherine Belendiuk, PhD1, Laura Gaetano, PhD2, Jumaah Goldberg, DPT1, Nicole Bonine, PhD, MPH1, Gillian Hanson, ND3, Kieran Mace, PhD3 and Yifeng Jenny Chia, PhD1, (1)Genentech, Inc., South San Francisco, CA, (2)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (3)PicnicHealth, San Francisco, CA - NNN05
Validation of Paced Auditory Serial Addition Test (PASAT) Regression Normative Data for Performance and Cognitive Fatigability in Multiple Sclerosis
Caitlin S Walker, H.BA., Carleton University, Ottawa, ON, Canada, Jason A Berard, PhD, Neuroscience, Ottawa Hosptial Research Institute, Ottawa, ON, Canada and Lisa A.S. Walker, Ph.D., The Ottawa Hospital Research Institute, Ottawa, ON, Canada - NNN06
Synesthesia May be Prevalent in Multiple Sclerosis
Melissa Villafana, B.A.1, Glenn R Wylie, Ph.D.2 and Ruth E Propper, Ph.D.1, (1)Psychology, Montclair State University, Montclair, NJ, (2)Rocco Ortenzio Neuroimaging Center, Kessler Foundation, West Orange, NJ - NNN07
Examining the Influence of Processing Speed on the Relation between Backward Walking and Falls in Persons with Multiple Sclerosis
Erin M Edwards, B.S.1, Ana M Daugherty, PhD2 and Nora E Fritz, PhD, PT, DPT, NCS1, (1)Neuroimaging and Neurorehabilitation Laboratory, Wayne State University, Detroit, MI, (2)Psychology, Wayne State University, Detroit, MI - NNN08
Longitudinal Olfactory Patterns in Multiple Sclerosis: A Scoping Review and Implications for Use in Management of Disease
Lauren L Frederick, BS1, Ram Sivakumar, BS1, Sharon G Lynch, MD2 and Jennifer Villwock, MD3, (1)University of Kansas Medical Center, Kansas City, KS, (2)Neurology, University of Kansas Medical Center, Kansas City, KS, (3)Otolaryngology, University of Kansas Medical Center, Kansas City, KS - NNN09
Negative Dual Task Effects Can be Similar in People with Multiple Sclerosis and Controls, but Depend on Processing Time, Not Single Task Performance
Sheri L Bunyan, PhD, PT1,2 and Alexander V Ng, PhD2, (1)Physical Therapy, University of Wisconsin – Stevens Point, Stevens Point, WI, (2)Exercise Science, Marquette University, Milwaukee, WI
Neuropathology and Pathogenesis
- NPP01
Oligoclonal Band Negative Multiple Sclerosis in Puerto Rico
Evián Pérez Rivera, BS1, Casey K Gilman, BS1, Viviana Martinez Maldonado, BS2, Ramón Vega Corteguera, BS2, Paulina Díaz de la Matta, MA3, Ivonne Vicente Loperena, MD2 and Angel Chinea, MD4, (1)San Juan Bautista School of Medicine, Caguas, PR, (2)San Juan Multiple Sclerosis Center, Guaynabo, PR, (3)Universidad Central del Caribe, Bayamón, PR, (4)San Juan MS Center, Guaynabo, PR, Puerto Rico - NPP02
Altered Expression of the RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein A1 (A1) Contributes to the Pathogenesis of Neurodegeneration in Multiple Sclerosis
Amber Anees, BSc., Health Sciences, University of Saskatchewan, Saskatoon, SK, Canada, Michael Levin, FRCPC, Office of the Saskatchewan Multiple Sclerosis Clinical Research Chair, University of Saskatchewan, Saskatoon, SK, Canada, Hannah E Salapa, PhD, Anatomy, Physiology and Pharmacology, University of Saskatchewan, Saskatoon, SK, Canada and Patricia Thibault, PhD, University of Saskatchewan, Saskatoon, SK, Canada
Programs
- PGM01
The Influence of Tethered and Joint HCP and Patient Education on Clinical Practice Behavior, Patient Activation, and Empowerment
Carole Drexel, PhD1, Elizabeth L. del Nido, BA1, Scott D. Newsome, DO, MSCS, FAAN, FANA2, June Halper, MSN, APN-C, MSCN, FAAN3 and Wendy Turell, DrPH1, (1)PlatformQ Health Education, Needham, MA, (2)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (3)Consortium of Multiple Sclerosis Centers, Hackensack, NJ - PGM02
Impact of a Virtual Wellness Program on Quality-of-Life Measures for Patients Living with MS during the COVID-19 Pandemic
Dina Jacobs, MD1, Nora Garland, MSW, LSW1, Vanessa Zimmerman, MSN, RN, MSCN1 and Sarah M Weinstein, MS2, (1)Neurology, University of Pennsylvania, Philadelphia, PA, (2)Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA - PGM03
National MS Society Black MS Experience Summit, a Culturally Responsive Virtual Education Program for People Affected By MS
Eric Garmon, MCHES, MS Navigator Experience, National MS Society, Denver, CO and Hooper K, Marshall J, Stewart K - PGM04
National MS Society Ask an MS Expert Offers Virtual Education Programing for People Affected By MS
Eric Garmon, MCHES, MS Navigator Experience, National MS Society, Denver, CO and Liserio E, Tauchman J, Fiol J, Szafran E, Barnola A, Costello K - PGM05
National MS Society Facebook Community Offers Connection and Virtual Education Options for People Affected By MSEric Garmon, MCHES, MS Navigator Experience, National MS Society, Denver, CO and Liserio E, Tauchman J, Herrmann B, Anzada P, Benson T, Gasper-Krueger A, Baker C, Cohrs R, Jensen A, Roper E, Ovsepian N - PGM06
Knowledge, Skills, and Confidence of Healthcare Professionals Participating in the Echo MS Program
Kevin N Alschuler, PhD1,2, Darren Ball, M.Ed.3, Annette Wundes, MD4, Salim Chahin, MD5, Mark Skeen, MD6 and Gloria von Geldern, MD4, (1)Department of Neurology, University of Washington School of Medicine, Seattle, WA, (2)Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA, (3)National Multiple Sclerosis Society, New York, NY, (4)Neurology, University of Washington, Seattle, WA, (5)Washington University in St. Louis, St. Louis, MO, (6)Neurology, Duke University, Durham, NC - PGM07
Improving MS Care through Educational Outreach to Generalists
Lynda R Hillman, DNP, MS Center of Excellence, West, VA Puget Sound Healthcare, Seattle, WA and Nancy Harris, MN, RN, VA-ECHO, VA Puget Sound Healthcare System, Seattle, WA - PGM08
Regional MS Summit to Improve Access to High Quality MS Care
Piper Reynolds, BS, Director Healthcare Provider Engagement, National Multiple Sclerosis Society, New York, NY, Gloria von Geldern, MD, Neurology, University of Washington, Seattle, WA, Lucas McCarthy, MD, MS, Virginia Mason, Seattle, WA, Annette Wundes, MD, University of Washington, Seattle, WA, Jodie K Haselkorn, MD, MPH, Department of Epidemiology, University of Washington, Seattle, WA, Angeli Mayadev, MD, MS Center, Swedish Medical Center, Seattle, WA, Stacy Donlon, MD, MultiCare Neuroscience, Tacoma, WA, Kathleen Burgess, MD, VA MS Center of Excellence-West, Seattle, WA and Lynda R Hillman, DNP, MS Center of Excellence, West, VA Puget Sound Healthcare, Seattle, WA - PGM09
The Multiple Sclerosis at Home Access Program (MAHA): New Challenges for Those Living with Multiple Sclerosis and Significant Disability during the COVID-19 Pandemic
Renee Stewart, DNP, APRN-NP1, Rana K. Zabad, MD2, Kristen Bayly, BSN1, Aubrie L Lindner, AA3, Kathleen Healey, NP, PhD4 and Mohamed Darwish, MD5, (1)Neurological Sciences, Nebraska Medicine, Omaha, NE, (2)Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, (3)Neurological Sciences Program Operations Manager, Nebraska Medicine, Omaha, NE, (4)Neurological Sciences, University of Nebraska, Omaha, NE, (5)Department of Neurology, University Nebraska Medical Center, Omaha, NE - PGM10
Continued Expansion of a Multiple Sclerosis Pharmacy Program
Stacy Tyrrell, PharmD, BCACP1, Shannon Panther, PharmD, BCACP2, Aimie Inthoulay, BA3 and Jason Chau, PharmD, MSCS, BCPS, BCACP3, (1)Kaiser Permanente, Tacoma, WA, (2)Kaiser Permanente, Spokane, WA, (3)Kaiser Permanente, Renton, WA
Psychosocial Factors
- PSY09
Attitudes Toward Biobanking Among Persons with MS
Alexa Stuifbergen, PhD, RN, FAAN, Nico Osier, PhD, RN, Sungju M Lim, MSN, Heather Becker, PhD, Research Scientist and Eliana Gill, BSN, School of Nursing, The University of Texas at Austin, Austin, TX - PSY10
Multiple Sclerosis, Patient Reported Meaning and Purpose: The Relationship of Physical Ability to Patient Reported Quality of Life
Olivia Kaczmarek, BS1, Avtej Sethi, MS2, Gina Koch, Student2, Barbara Bumstead, MS, ANCP, MSCN2, Marijean Buhse, NP-C, PhD1, Myassar Zarif, MD1, Jeffrey Wilken, PhD3, Daniel Golan, MD4 and Mark Gudesblatt, MD5, (1)South Shore Neurologic Associates, Patchogue, NY, (2)South Shore Neurologic Associates, P.C., Patchogue, NY, (3)Washington Neuropsychology Research Group, Washington, DC, (4)Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, (5)South Shore Neurologic Associates, P.C., Islip, NY - PSY11
Establishing the Test-Retest Reliability and Minimal Detectable Change of the Multiple Sclerosis Resiliency Scale (MSRS)
Elizabeth S Gromisch, PhD1,2,3, Aaron P Turner, Ph.D. ABPP (RP)4,5,6, Lindsay O Neto, MPH1,7, Jennifer A. Ruiz, DPT1,3, Albert C. Lo, MD, PhD1, Thomas P Agresta, MD, MBI8,9 and Frederick W Foley, Ph.D.10,11, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (2)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT, (3)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (4)Department of Rehabilitation Medicine, University of Washington, Seattle, WA, (5)Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, WA, (6)Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, WA, (7)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (8)Department of Family Medicine, University of Connecticut Health Center, Farmington, CT, (9)Center for Quantitative Medicine, University of Connecticut Health Center, Farmington, CT, (10)Holy Name Medical Center, Teaneck, NJ, (11)Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY - PSY12
Identifying Behavioral Targets to Reduce Missed Multiple Sclerosis-Related Appointments: Potential Implications for Interventions
Elizabeth S Gromisch, PhD1,2,3, Jodie K Haselkorn, MD, MPH4,5,6,7, Sarah A Raskin, PhD8,9, Lindsay O Neto, MPH1,10 and Aaron P Turner, Ph.D. ABPP (RP)4,5,7, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (2)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT, (3)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (4)Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, WA, (5)Department of Rehabilitation Medicine, University of Washington, Seattle, WA, (6)Department of Epidemiology, University of Washington, Seattle, WA, (7)Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, WA, (8)Neuroscience Program, Trinity College, Hartford, CT, (9)Department of Psychology, Trinity College, Hartford, CT, (10)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT - PSY13
COVID-19 Impact on Loneliness and Rates of Depression and Anxiety in Individuals with MS
Erica Weber, PhD, Anthony Lequerica, PhD and Lauren B Strober, Ph.D., Kessler Foundation, East Hanover, NJ - PSY14
Association of Social Support with Resilience As Moderated By Depression, Anxiety, and Personality in Multiple Sclerosis Patients
Joelle Massouh, MSN, MSCN, Beirut, Lebanon - PSY15
Styles of Coping, Wellbeing, and Perceived Stress in Persons with Multiple Sclerosis during the COVID-19 Pandemic: The Role of Self-Compassion and Personality
Nina Rose, MA, Clinical Health Psychology PhD, Ferkauf Graduate School of Professional Psychology, Brooklyn Heights, NY - PSY16
A Continuum of Languishing to Flourishing: A Qualitative Study of Psychological Resilience in Multiple Sclerosis Family Caregivers
Odessa J. McKenna, MSc1,2, Afolasade Fakolade, PhD3, Katherine L. Cardwell, BHSc1 and Lara A. Pilutti, PhD1,4, (1)Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada, (2)Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada, (3)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, (4)Brain and Mind Research Institute, University of Ottawa, Ottawa, ON, Canada - PSY18
Association of Lifestyle Physical Activity with Physical and Cognitive Fatigue in Individuals with Relapsing Remitting Multiple Sclerosis
Babita Bisht, PT, PhD1, Tyler J. Titcomb, PhD, RDN1, Warren G Darling, PhD2, Lucas J Carr, PhD2, Karin F. Hoth, PhD3, Patrick Ten Eyck, PhD4, Linda Rubenstein, PhD5, John A Kamholz, MD, PhD6, Linda G. Snetselaar, PhD, RDN5 and Terry L. Wahls, MD1, (1)Department of Internal Medicine, University of Iowa, Iowa City, IA, (2)Department of Health and Human Physiology, University of Iowa, Iowa City, IA, (3)Department of Psychiatry, University of Iowa, Iowa City, IA, (4)Institute for Clinical and Translational Science, University of Iowa, Iowa City, IA, (5)Department of Epidemiology, University of Iowa, Iowa City, IA, (6)Neurology, University of Iowa, Iowa City, IA - PSY19
MS Is Just like a Family Member: An Interpretative Phenomenological Analysis of the Lived Experiences of Multiple Sclerosis
Dinika Anand, Masters, New Delhi, India, Soumi Awasthy, PhD, Defence Institute of Psychological Research, New Delhi, India and Rajiv Anand, MD, Dr. B.L.Kapoor Superspeciality Hospital, New Delhi, India - PSY20
Place and Race Disparities in MS Healthcare
Jagriti ‘Jackie’ Bhattarai, PhD, MS, Physical Medicine and Rehabilitation, Johns Hopkins School of Medicine, Baltimore, MD - PSY21
Cognitive Fatigability and Cardiorespiratory Fitness in Persons with Advanced Multiple Sclerosis
Zain Awadia, BHSc, Faculty of Health Sciences, University of Ottawa, Ottawa, ON, Canada, Thomas Edwards, MSc, School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada, Jason A Berard, PhD, Neuroscience, Ottawa Hosptial Research Institute, Ottawa, ON, Canada, Lisa A.S. Walker, Ph.D., The Ottawa Hospital Research Institute, Ottawa, ON, Canada and Lara A. Pilutti, PhD, Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada
Quality of Life
- QOL01
Gratitude, Perceived Stress, and Quality of Life Among Patients with MS
Afiah Hasnie, Psy.D., Neurology, Cleveland Clinic Mellen Center for MS, Cleveland, OH - QOL02 Fatigue Evolution for Patients without Relapses on the Fsiq-RMS Symptoms Domain
Alexander J. Keenan, MA, MHP1, Tatiana Scherz, MD2, Brian Hennessy, PhD2, Hilke Kracker, PhD2 and Janssen R&D, (1)Janssen Research & Development, Titusville, NJ, (2)Janssen R&D, Allschwil, Switzerland - QOL03
Direct Cost Associated with Multiple Sclerosis and Important Components; A Population-Based Study 1997-2017
Amir Khakban, Msc., Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, Elisabet Rodriguez Llorian, PhD, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, Scott B Patten, MD, PhD, Community Health Sciences & Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada, Anthony L. Traboulsee, MD, Neurology, The University of British Columbia, Vancouver, BC, Canada and Larry Lynd, PhD, . Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada - QOL04
Multiple Sclerosis: The Relationship of Cognitive Impairment and Self-Efficacy of Medication Management
Avtej Sethi, MS1, Olivia Kaczmarek, BS2, Jack Petroski, Student1, Emma Malone, Student1, Barbara Bumstead, MS, ANCP, MSCN1, Marijean Buhse, NP-C, PhD2, Myassar Zarif, MD2, Daniel Golan, MD3, Jeffrey Wilken, PhD4 and Mark Gudesblatt, MD5, (1)South Shore Neurologic Associates, P.C., Patchogue, NY, (2)South Shore Neurologic Associates, Patchogue, NY, (3)Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, (4)Washington Neuropsychology Research Group, Washington, DC, (5)South Shore Neurologic Associates, P.C., Islip, NY - QOL05
Improving Health Outcomes of MS Patients during the Pandemic
Beth Schneider, Senior Research Director, MyHealthTeams, San Francisco, CA - QOL06
Assessing Presence of MS-Related Symptoms As a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data
Barry Hendin, MD, Phoenix Neurological Associates, Phoenix, AZ; Neurology, University of Arizona, Tucson, AZ, Richard A. Brook, MS, MBA, Better Health Worldwide, Inc., Newfoundland, NJ, Ian A. Beren, BS, WorkPartners, LLC, Loveland, CO, Nathan L. Kleinman, PhD, WorkPartners, LLC, Cheyenne, WY, Amy L. Phillips, PharmD, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Rockland, MA and Carroline Lobo, PhD, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, MA, Germany - QOL07
Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis
Barry Hendin, MD, Neurology, University of Arizona, Tucson, AZ, Richard A. Brook, MS, MBA, Better Health Worldwide, Inc., Newfoundland, NJ, Ian A. Beren, BS, WorkPartners, LLC, Loveland, CO, Nathan L. Kleinman, PhD, WorkPartners, LLC, Cheyenne, WY, Cindy Fink, BSc, Care Partner Adviser, Cleveland Heights, OH, Amy L. Phillips, PharmD, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany, Rockland, MA and Carroline Lobo, PhD, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Darmstadt, MA, Germany - QOL08
Patient Reported Outcomes from Pharmacist-Led Multiple Sclerosis Assessments in a Specialty Pharmacy Setting
Craig Riccardo, PharmD, CSP, MSCS and Kate Jelline, PharmD, MSCS, CSP, Ardon Health, Portland, OR - QOL09
Examining Fatigue in Progressive MS: Results from a Qualitative Study and Review of PRO Measures
Crystal Watson, MS1, Kayla Scippa, BA2, Arie Barlev, PharmD1 and Jason C Cole, PhD2, (1)Atara Biotherapuetics, South San Francisco, CA, (2)ZS Associates, Thousand Oaks, CA - QOL10
Assessing Patient-Reported Outcomes and Pharmacist Interventions in Multiple Sclerosis within an Integrated Care Center
Danielle Bryan, PharmD1, Rebekah Finley, PharmD candidate2, Autumn Zuckerman, PharmD, BCPS, AAHIVP, CSP1, Megan Peter, PhD1, Ryan Moore, MS3 and Leena Choi, PhD3, (1)Vanderbilt Specialty Pharmacy, Vanderbilt University Medical Center, Nashville, TN, (2)Lipscomb University, Nashville, TN, (3)Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN - QOL11
Integrating User Experience Improves Participant Engagement: A Co-Design Initiative in the Multiple Sclerosis Continuous Quality Improvement (MS-CQI) Improvement Research Collaborative.
Eleanor Bryan, M.Ed1, Falguni Mehta, MS, MBA1 and Brant J. Oliver, PhD, MS, MPH, APRN-BC2, (1)Department of Community & Family Medicine, Dartmouth Hitchcock Health, Lebanon, NH, (2)Geisel School of Medicine at Dartmouth, Lebanon, NH - QOL12
Health and Wellness Needs Reported to Influence Quality of Life in People with Relapsing-Remitting Multiple Sclerosis, a Qualitative Investigation
Erin M Faraclas, PT, DPT, PhD(c), MSCS, Doctor of Philosophy in Health Sciences Program, Rocky Mountain University, Provo, UT; School of Physical Therapy, MCPHS, Worcester, MA, Angela Merlo, PT, DPT, PhD, Department of Physical Therapy, Eastern Washington University, Spokane, WA, Jeffery Lau, PT, DPT, PhD, College of Rehabilitation Sciences, Rocky Mountain University, Provo, UT and Jeff Lynn, PhD, Slippery Rock University, Slippery Rock, PA - QOL13
An Update on Participants in the Iconquerms Network.
Farren B.S. Briggs, PhD, ScM1, Nina Bozinov, MD, MS2, Robert N. McBurney, PhD3, Hollie Schmidt, MS4, Laura Kolaczkowski, BA3 and Sara Loud, MSEE, MBA4, (1)Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, (2)Neurology, Kootenai Clinic, Coeur d’Alene, ID, (3)Accelerated Cure Project for MS, Waltham, MA, (4)Accelerated Cure Project for Multiple Sclerosis, Waltham, MA - QOL14
The Relationship between Illness Intrusiveness and Walking in Persons with Multiple Sclerosis
Heather M DelMastro, MSc1,2, Jennifer A. Ruiz, DPT1,3 and Elizabeth S Gromisch, PhD1,3,4, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (2)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (3)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (4)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT - QOL15
Differences in Expected Number of Clinical Management Events before and during Treatment with Sphingosine-1-Phosphate Receptor Modulators for Multiple Sclerosis
Jennifer S. Harper, PhD, MS1, Nayad T. Manukian, MS1, David M. Kern, PhD2, Smita Mitra, PhD1, Alex Z. Fu, PhD, MS3, Hoa H. Le, PhD4, Allitia DiBernardo, MD1 and John J. Sheehan, Phd, RPh3, (1)Janssen Pharmaceuticals, Inc., Titusville, NJ, (2)Janssen Research & Development, LLC, Titusville, NJ, (3)Janssen Scientific Affairs, LLC, Titusville, NJ, (4)Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, NJ - QOL16
Empowering Patients through Technology to Manage and Track Symptoms of MS
Elaine Rudell, CHCP1, Tarjani Agrawal, PhD1, Patty Peterson, BS2, Andrea L. Griffin, BS3, Michele Fallon Ingram, BS1 and James Bowen, MD4, (1)@Point of Care, Short Hills, NJ, (2)Projects In Knowledge, Short Hills, NJ, (3)Multiple Sclerosis Association of America, Cherry Hill, NJ, (4)Swedish Neuroscience Institute, Seattle, WA - QOL17
Virtual I Can Do It Program for Individuals with Progressed Multiple Sclerosis
Joan Augustyn, OTD, OTR/L, McKara Shaw, OTS, Anna Watkins, OTS, Madeline Mason, OTS and Justina Bayless, OTS, Occupational Therapy Education and MS Achievement Center, University of Kansas Medical Center, Kansas City, KS - QOL18
The Can Do Multiple Sclerosis Outcomes Study: Study Design to Evaluate Program Outcomes
Kathleen Costello, MS, CRNP, MSCN, Programs, Can Do Multiple Sclerosis, Avon, CO - QOL19
Perceived Health Related Quality of Life and Healthcare Resource Utilization in Persons with Multiple Sclerosis with and without Vascular Comorbidity
Lindsay O Neto, MPH1,2, Jennifer A. Ruiz, DPT1,3 and Elizabeth S Gromisch, PhD1,3,4, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (2)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (3)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (4)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT - QOL20
A Real-World Study Characterizing Symptoms and Impacts of Fatigue in US Adults with Relapsing Multiple Sclerosis Using a Novel Disease Specific Scale
Lindsey Lair, MD1, Tiphaine Lévy-Heidmann, MSc2, Valentin Morisseau, MSc2, Carol Jamieson, BSc3, Leigh E Charvet, PhD4, Lauren B. Krupp, MD5 and Marion Azoulai, MSc2, (1)Janssen Research & Development, LLC, Titusville, NJ, (2)Carenity, Paris, France, (3)Janssen Research & Development, LLC, Milpitas, CA, (4)Neurology, NYU Langone Health, New York, NY, (5)Neurology, New York University Langone Medical Center, New York, NY - QOL21
Telehealth Utilization and Clinical Outcomes in Four MS Centers during the COVID Pandemic: Real-World Evidence from the MS-Cqi Improvement Research Collaborative.
Matthew Molaei, PharmD1, Anna Chen, PharmD1, Anna Vaeth, BS2, Karen Walsh, MS, MBA1 and Brant J. Oliver, PhD, MS, MPH, APRN-BC3, (1)College of Population Health, Thomas Jefferson University, Philadelphia, PA, (2)Multiple Sclerosis Imaging Center, Dept. of Neurology, Massachusetts General Hospital; Harvard Medical School, Charlestown, MA, (3)Geisel School of Medicine at Dartmouth, Lebanon, NH - QOL22
Evaluating the Impact of Fatigue Symptoms on Work Productivity and Activity Impairment Using Longitudinal Data from the Phase III Optimum Study
Alex Keenan, MS1, Hoa Le, PhD2, Christopher Pelligra, PhD3, Ibrahim Turkoz, PhD4, Shien Guo, PhD5, Weiqin Liao, PhD5 and Michele Cole, PharmD, MS1, (1)Research and Development, Janssen Pharmaceuticals, Titusville, NJ, (2)Janssen Scientific Affairs, Janssen Pharmaceuticals, Titusville, NJ, (3)Evidence Synthesis, Modeling and Communication, Evidera, Bethesda, MD, (4)Janssen Research & Development, Titusville, NJ, (5)Evidence, Value and Access, Evidera, Bethesda, MD - QOL23
Assessing the Impact of Disease Activity and Fatigue Symptom on Work Productivity and Activity Impairment in Patients with Relapsing Multiple Sclerosis
Michele Cole, PharmD, MS1, Alexander J. Keenan, MA, MHP2, Hoa Le, PhD3, Christopher Pelligra, PhD4, Shien Guo, PhD5 and Weiqin Liao, PhD5, (1)Research and Development, Janssen Pharmaceuticals, Titusville, NJ, (2)Janssen Research & Development, Titusville, NJ, (3)Janssen Scientific Affairs, Janssen Pharmaceuticals, Titusville, NJ, (4)Evidence Synthesis, Modeling and Communication, Evidera, Bethesda, MD, (5)Evidence, Value and Access, Evidera, Bethesda, MD - QOL24
Improving Communication about Multiple Sclerosis: The MS-Support Decision Aid
Nananda Col, MD, MPH., MPP, FACP1, Christina Fitzpatrick, MA1, Enrique Alvarez, MD2, Lori Pbert, PhD3, Carolina Ionete, MD, PhD4, Idanis Berrios Morales, MD5, Andrew J. Solomon, MD6, Christen Kutz, PhD, PA-C7, Terrie Livingston, PharmD8, Jennifer Chester, FNP-BC, MSCN9, Crystal Iwuchukwu, RN, BSN, FNP10 and Long Ngo, MD11, (1)Shared Decision Making Resources, Georgetown, ME, (2)University of Colorado, Denver, CO, (3)University of Massachusetts Medical School, Worcester, MA, (4)University of Massachusetts Memorial Medical Center, Worcester, MA, (5)University of Massachusetts Medical Center, Worcester, MA, (6)Neurological Sciences, Larner College of Medicine at the University of Vermont, Burlington, VT, (7)Colorado Springs Neurological Associates, Colorado Springs, CO, (8)EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, MA, Germany, (9)Kansas City MS Center at College Park Specialty, Overland Park, KS, (10)Southeast Health, Cape Girardeau, MO, (11)Beth Israel Deaconess Medical Center, Boston, MA - QOL25
Factors Associated with Stigma in People with Multiple Sclerosis.
Nina Bozinov, MD, MS, Neurology, Kootenai Clinic, Coeur d’Alene, ID and Farren B.S. Briggs, PhD, ScM, Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH - QOL26
Multiple Sclerosis, Cognition and the Ability to Participate in Social Roles and Activities: Disease Impact Beyond Physical Disability
Olivia Kaczmarek, BS1, Jack Petroski, Student2, Colette Kodym, Student2, Avtej Sethi, MS2, Barbara Bumstead, MS, ANCP, MSCN2, Marijean Buhse, NP-C, PhD1,3, Myassar Zarif, MD1, Daniel Golan, MD4, Jeffrey Wilken, PhD5 and Mark Gudesblatt, MD6, (1)South Shore Neurologic Associates, Patchogue, NY, (2)South Shore Neurologic Associates, P.C., Patchogue, NY, (3)Stony Brook University, Stony Brook, NY, (4)Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, (5)Washington Neuropsychology Research Group, Washington, DC, (6)South Shore Neurologic Associates, P.C., Islip, NY - QOL27
Multiple Sclerosis and the Ability to Participate in Social Roles and Activities: Disease Impact Beyond Physical Disability
Olivia Kaczmarek, BS1, Ellie Teng, Student2, Fatima Khan, Student2, Avtej Sethi, MS2, Barbara Bumstead, MS, ANCP, MSCN2, Marijean Buhse, NP-C, PhD1, Myassar Zarif, MD1, Daniel Golan, MD3, Jeffrey Wilken, PhD4 and Mark Gudesblatt, MD5, (1)South Shore Neurologic Associates, Patchogue, NY, (2)South Shore Neurologic Associates, P.C., Patchogue, NY, (3)Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, (4)Washington Neuropsychology Research Group, Washington, DC, (5)South Shore Neurologic Associates, P.C., Islip, NY - QOL28
Characterizing Activities of Daily Living in MS Patients with Processing Speed Scores Above and below a Threshold Previously Shown to Predict Employment Status
Ralph H.B. Benedict, PhD1, Arman Altincatal, MS2, Enrique Alvarez, MD, PhD, MSCI3, Deborah Backus, PT, PhD4, Martin Belkin, DO5, Sophie Cleanthous, PhD6, Joanna Cooper, MD7, Jessica Craddock, MD8, Carl de Moor, PhD2, Emma Elliott, BSc6, John Foley, MD9, Mehul Jhaveri, PharmD, MPH2, Gabriel Pardo, MD, FAAN10, Christopher Perrone, MD11, Pavle Repovic, MD, PhD12, Marvin Rock, –2, Suma Shah, MD13, Barry A Singer, MD14, Jacob A Sloane, MD PhD15, Kyle E. Smoot, MD16, Carlo Tornatore, MD17, Bianca Weinstock-Goodman, MD18 and Irene Koulinska, MD, ScD2, (1)Jacobs Multiple Sclerosis Center, University at Buffalo, Buffalo, NY, (2)Biogen, Cambridge, MA, (3)Department of Neurology, University of Colorado, Aurora, CO, (4)MS Research, Shepherd Center, Atlanta, GA, (5)Michigan Institute for Neuro Disorders, Farmington Hills, MI, (6)Modus Outcomes, Letchworth Garden City, United Kingdom, (7)East Bay Neurology, Walnut Creek, CA, (8)Providence Sacred Heart Medical Center – Spokane, Spokane, WA, (9)Rocky Mountain MS Clinic, Salt Lake City, UT, (10)Oklahoma Medical Research Foundation, Oklahoma City, OK, (11)OMRF Multiple Sclerosis Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, (12)Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, (13)Neurology, Duke University, Durham, NC, (14)Barnes Jewish Hospital, St Louis, OH, (15)Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, (16)Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR, (17)Department of Neurology, Medstar Georgetown University Hospital, Washington, DC, (18)Jacobs Multiple Sclerosis Center, University of Buffalo, Buffalo, NY - QOL29
A Coach Supported Standardized Approach for Quality Improvement (QI) in the Multiple Sclerosis Continuous Quality Improvement (MS-CQI) Research Collaborative.
Randall S Messier, MT, MSA, PCMH CCE, RandyMessierLLC, Fairfield, VT, Falguni Mehta, MS, MBA, Department of Community & Family Medicine, Dartmouth Hitchcock Health, Lebanon, NH and Brant J. Oliver, PhD, MS, MPH, APRN-BC, Geisel School of Medicine at Dartmouth, Lebanon, NH - QOL30
Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Multiple Sclerosis
Richard A. Brook, MS, MBA, Better Health Worldwide, Inc., Newfoundland, NJ, Nathan L. Kleinman, PhD, WorkPartners, LLC, Cheyenne, WY and Ian A. Beren, BS, WorkPartners, LLC, Loveland, CO - QOL31
The Importance of Specialty Pharmacy Services in Multiple Sclerosis Patient Care
Roma Amin, PharmD, BCACP1, LaTasha Riddick, PharmD, BCACP1, Amy Nathanson, PharmD, BCACP1 and Scott D. Newsome, DO, MSCS, FAAN, FANA2, (1)Johns Hopkins Homecare Group, Baltimore, MD, (2)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD - QOL32
Understanding MS Symptoms and Impacts through Semi-Structured Interviews with Clinical Experts and People Living with MS
Susanne Clinch, PhD1, Fiona McDougall, PhD2, Amy Barrett, MSPH, MA3, Oyebimpe Olayinka-Amao, PharmD, MPH3, Licinio Craveiro, MD, MSc, PhD4, Mike Baker, BSc, MSc4 and Michael Lindemann, MD, PhD4, (1)Roche Products Limited, Welwyn Garden City, United Kingdom, (2)Genentech, Inc., South San Francisco, CA, (3)RTI Health Solutions, Research Triangle Park, NC, (4)F. Hoffmann-La Roche Ltd, Basel, Switzerland - QOL33
Adherence to Oral Disease Modifying Therapies in Clinical Practice and Patient-Centered Outcomes
Suzanne Croll, BSc1, Omar M Said, BS1,2, Marta Zholobetska, BS1, Lonni Schultz, PhD3 and Mirela Cerghet, MD, PhD2, (1)Neurology, Henry Ford Hospital, Detroit, MI, (2)School of Medicine, Wayne State University, Detroit, MI, (3)Public Health Science, Henry Ford Health System, Detroit, MI - QOL35
Patient-Reported Outcome Measures in Multiple Sclerosis Clinical Trials: Critical Assessment and Insights from People Living with Multiple Sclerosis
Trishna Bharadia, BA (Hons)1, Tanuja Chitnis, MD2, Piet Eelen, RN MSc3, Birgit Bauer, .4, Giampaolo Brichetto, MD, PhD5, Andrew Lloyd, DPhil6, Hollie Schmidt, MS7, Miriam King, BA (Hons)8, Jenny Fitzgerald, BSc8, Thomas Hach, MD8, Jo Vandercappellen, PhD, MBA8 and Jeremy Hobart, BSc, PhD9, (1)Marlow, United Kingdom, (2)Brigham and Women’s Hospital, Department of Neurology, Boston, MA, (3)National Multiple Sclerosis Center of Melsbroek, Flanders, Belgium, (4)Manufaktur für Antworten (UG), Abensberg, Germany, (5)Associazione Italiana Sclerosi Multipla Rehabilitation Center, Genoa, Italy, (6)Acaster Lloyd Consulting Ltd, London, United Kingdom, (7)Accelerated Cure Project for Multiple Sclerosis, Waltham, MA, (8)Novartis Pharma AG, Basel, Switzerland, (9)Peninsula Schools of Medicine and Dentistry, University of Plymouth, Plymouth, United Kingdom - QOL36
Effects, Tolerance, and Response to COVID-19 Vaccines in Hispanic Puerto Rican Patients with Multiple Sclerosis
Viviana Martínez-Maldonado, BS1, Ramon J Vega-Corteguera, BS2, Paulina Díaz de la Matta, MA3, Ivonne Vicente, MD1 and Angel Chinea, MD1, (1)San Juan MS Center, Guaynabo, PR, Puerto Rico, (2)San Juan MS Center, Guaynabo, Puerto Rico, (3)Universidad Central del Caribe, Bayamón, PR - QOL37
Understanding Health and Well-Being of Women with MS: Implications for Health Care Providers
Jennifer L Howard, PhD(c)., RN, Faculty of Nursing, Memorial University of Newfoundland, St. John’s, NF, Canada, Yolanda Babenko-Mould, PhD, RN, Health Science-Nursing, Western University, London, ON, Canada, Kimberley Jackson, PhD, RN, Health Science- Nursing, Western University, London, ON, Canada and Tracy Smith-Carrier, PhD, RSW, Social Work, King’s University College at Western University, London, ON, Canada - QOL38
Coping Moderates the Association between Symptoms and Functional and Affective Outcomes in the Daily Lives of Individuals with Multiple Sclerosis
Thomas R Valentine, PhD, Duygu Kuzu, PhD and Anna L Kratz, PhD, Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI - QOL39
Multiple Sclerosis Specialist Nurse Care: Patterns of Access and Impact on Health Outcomes
Belinda Bardsley, RN BN MSCN Dip Management1,2, Therese V Burke, PhD RN CNC3, Jing Chen, PhD4, Bruce Taylor, MD FRACP4, Sue Shapland, RN BN MSCN5 and Ingrid van der Mei, PhD4, (1)Neurology, Austin Health, Heidelberg, VIC, Australia, (2)MS Nurses Australasia Incorporated, Melbourne, Australia, (3)MS Research Australia, North Sydney, Australia, (4)Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia, (5)MSWA, Perth, Australia
Rehabilitation
- REH09
Attitude and Perception of Multiple Sclerosis Patients Toward Exercise Ali Fuad Ashour, PhD and Ali Fuad Ashour, PhD, Ministry of Education, Kuwait, Kuwait - REH10
Is Depression Associated with Volume and Pattern of Sedentary Behavior in Persons with Multiple Sclerosis?
Catherine D Jones, MSPH1, Brenda Jeng, MS2, Katie LJ Cederberg, PhD3, Morghen Sikes, PhD, OT4, Jeffer E Sasaki, PhD5 and Rob Motl, PhD1, (1)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (3)Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, (4)Physical Therapy, UAB, Birmingham, AL, (5)Sports Sciences, Universidade Federal do Triângulo Mineiro, Uberaba, Brazil - REH11
A Scoping Review of Task-Oriented Exercise Effects on Motor Function in People with Multiple SclerosisEduardo A Toledo-Aldana, BSc, Kristen E Plandowski, BSc and Cameron S Mang, PhD, Kinesiology and Health Studies, University of Regina, Regina, SK, Canada - REH12
Physical Activity Vital Sign in Multiple Sclerosis
Gloria Hou, MD1, Jami Montagnino, MD1, Marcia Ciol, Ph.D.1 and Cindy Lin, MD1,2, (1)University of Washington, Seattle, WA, (2)The Sports Institute, Seattle, WA - REH13
Difference in Lower Limb Strength Asymmetry between Fallers and Non-Fallers with Multiple Sclerosis
Heather M DelMastro, MSc1,2, Elizabeth S Gromisch, PhD1,3,4 and Jennifer A. Ruiz, DPT1,4, (1)Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT, (2)Department of Rehabilitative Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, (3)Department of Neurology, University of Connecticut School of Medicine, Farmington, CT, (4)Departments of Rehabilitative Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT - REH14
Assessing the Benefits of Using Telehealth in Conjunction with a Fitbit to Improve Walking in Veterans with Multiple Sclerosis
Kelley Volpenhein, PT, DPT1, Amy Banks, PT, DPT, NCS, CBIS1, Lindsay J Riegler, Ph.D.2, Sarah Kiefer-Luhring, MA, CCC-SLP, ATP1 and Amy Kunce, MS, BSRS, CNMT3, (1)Cincinnati VAMC, Cincinnati, OH, (2)Rehab Care Line, Cincinnati VA Medical Center, Cincinnati, OH, (3)Neurology, VAMC, Baltimore, MD - REH15
Occupational Therapy Delivered Emotional Regulation Interventions: A Case-Series of Female Patients with Multiple Sclerosis
Rebecca Cunningham, OTD, OTR/L, MSCS, Mrs. T.H. Chan Division of Occupational Science & Occupational Therapy, University of Southern California, Los Angeles, CA and Kristin McConnell, MA, OTS, Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA - REH16
A Review of Participant Characteristics in Theory-Based Physical Activity Behavior Change Programs in MS: Missing the Greatest Potential for Lifelong Benefits
Trinh Huynh, MPH1, Stephanie L Silveira, PhD2 and Robert W Motl, PhD1, (1)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)Kinesiology, University of North Texas, Denton, TX - REH17
Needs and Perceptions of a Mobile Application Based on the Canadian Physical Activity Guidelines for Adults with Multiple Sclerosis in the United States
Whitney N Neal, MA, CHES1, Emma V Richardson, PhD2 and Robert W Motl, PhD1, (1)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)University of Worcester, Worcester, United Kingdom - REH18
Contradictory Roles of Exercise Participation: A Qualitative Synthesis
Brynn Adamson, PhD, Health Sciences, University of Colorado Colorado Springs, Colorado Springs, CO and Robert W Motl, PhD, Physical Therapy, University of Alabama at Birmingham, Birmingham, AL - REH19
Validation and Minimal Detectable Change of the Walking While Talking Test As a Measure of Dual-Task Performance in Ambulatory Individuals with Multiple Sclerosis
David A Henning, PhD1, Erin M Edwards, B.S.1, Melissa Ansara, undergraduate2 and Nora E Fritz, PhD, PT, DPT, NCS1, (1)Neuroimaging and Neurorehabilitation Laboratory, Wayne State University, Detroit, MI, (2)Physical Therapy, Wayne State University, Detroit, MI - REH20
Characterizing the Relationship between Neurological/Mental Health and Physical Activity Levels in Persons with Multiple Sclerosis
Emily E Tyszka, MPH, Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH and Farren B.S. Briggs, PhD, ScM, Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH - REH21
Effects of Extended Photobiomodulation Therapy on Muscle Performance in Persons with Relapsing-Remitting Multiple Sclerosis
Mitra Rouhani, M.S.1, Miguel Tolentino, Ph.D.2, Erik Queoff, M.S.1, Chris Cho, Ph.D.2, Jeri-Anne Lyons, Ph.D.2,3 and Alexander V Ng, PhD4, (1)Marquette University, Milwaukee, WI, (2)University of Wisconsin-Milwaukee, Milwaukee, WI, (3)University of Northern Colorado, Greeley, CO, (4)Exercise Science, Marquette University, Milwaukee, WI
Relapse Therapy
- RTH01
Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar
Benjamin M Greenberg, MD, MHS, FANA, FAAN1, Jerome de Seze, MD, PhD2, Albert Saiz, MD, PhD3, Takashi Yamamura, MD, PhD4, Michael Yeaman, PhD5, Carole Marcillat, PharmD6, Xiujing Kou, MD6, Kristina Weber, PhD6, Kathleen Blondeau, PhD6, Brian G Weinshenker, MD, FRCP(C)7 and Francesco Patti, MD, PhD8, (1)University of Texas Southwestern Medical Center, Dallas, TX, (2)Hôpital de Hautepierre, Strasbourg, France, (3)Service of Neurology, Hospital Clinic and Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain, (4)National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan, (5)Division of Molecular Medicine, Harbor-UCLA Medical Center, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, (6)F. Hoffmann-La Roche Ltd, Basel, Switzerland, (7)Mayo Clinic, Rochester, MN, (8)GF Ingrassia, Department, Neuroscience Section, University of Catania, Catania, Italy - RTH02
Results from a Multicenter, Randomized, Double Blind, Placebo-Controlled Study of Repository Corticotropin Injection for Relapsing-Remitting Multiple Sclerosis
Daniel Wynn, MD1, Lawrence P Goldstick, MD2, William Bauer, MD, PhD3, Enxu Zhao, MS4, Eva Tarau, MD4, Jeffrey A. Cohen, MD5, Derrick Robertson, MD6 and Aaron E Miller, MD7, (1)Consultants in Neurology MS Center, Northbrook, IL, (2)Waddell Center for Multiple Sclerosis, University of Cincinnati, Cincinnati, OH, (3)Department of Neurosciences, University of Toledo, Toledo, OH, (4)Mallinckrodt Pharmaceuticals, Hampton, NJ, (5)Department of Neurology, Mellen MS Center, Neurological Instiute,Cleveland Clinic, Cleveland, OH, (6)University of South Florida, Morsani College of Medicine, Tampa, FL, (7)Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, NY
Self-care
- SEC01
Summary of Diet Intervention Studies in Multiple Sclerosis from the National MS Society Nutrition Wellness Subgroup
Rebecca I Spain, MD, MSPH, Oregon Health & Science University, Portland, OR; VA Portland Health Care System, Portland, OR, Mona Bostick, RDN, LDN, MSCS, NA, Greensboro, NC, Patrizia Casaccia, MD, PhD, Advanced Science Research Center, City University of New York, New York, NY, Kathryn C Fitzgerald, ScD, Johns Hopkins Medicine, Department of Neurology, Baltimore, MD, Barbara Giesser, MD, Neurology, UCLA, Los Angeles, CA, Ellen M Mowry, MD, MCR, Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, Laura Piccio, MD/PhD, Neurology, Washington University, St Louis, MO, Terry L. Wahls, MD, Department of Internal Medicine, University of Iowa, Iowa City, IA, Brooks C Wingo, PhD, Department of Occupational Therapy, University of Alabama, Birmingham, AL, Vijayshree Yadav, MD, Neurology, Oregon Health & Science University, Portland, OR, Kathleen M Zackowski, PhD, OT, Motion Analysis Laboratory, Kennedy Krieger Institute, Baltimore, MD and Ilana Katz Sand, MD, Neurology, The Mount Sinai Hospital, New York, NY
Symptom Management
- SXM01
Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: A Randomized, Multi-Center, Placebo-Controlled Clinical Trial (Study OS440-3004)
Daniel Kantor, MD, FAAN, FANA, Florida Atlantic University, Boca Raton, FL, Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute, Franklin, TN, Mark Jaros, PhD, Summit Analytical, Denver, CO, Tina deVries, PhD, Osmotica Pharmaceuticals, Bridgewater, NJ and Darin T Okuda, MD, UT Southwestern Medical Center, Dallas, TX - SXM02
The Effect of Hypnotics and Stimulants on Fatigue, Sleep, and Quality of Life Outcomes in a Multiple Sclerosis Cohort
Daniela A Pimentel Maldonado, MD1, Loulwah Mukharesh, MD2, Chen Hu, MS1, Ellen M Mowry, MD, MCR1, Bardia Nourbakhsh, MD1 and Kathryn C Fitzgerald, ScD1, (1)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (2)Neuro-Ophthalmology, Massachusetts Eye and Ear Institute, Boston, MA - SXM03
Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: An Open-Label Safety Study (Study OS440-3005)
Darin T Okuda, MD, UT Southwestern Medical Center, Dallas, TX, Daniel Kantor, MD, FAAN, FANA, Florida Atlantic University, Boca Raton, FL, Mark Jaros, PhD, Summit Analytical, Denver, CO, Tina deVries, PhD, Osmotica Pharmaceuticals, Bridgewater, NJ and Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute, Franklin, TN - SXM04
Nabiximols, a Cannabis-Based Complex Botanical Mixture and MS Spasticity: How Does It Work?
Kathryn Nichol, PhD, Greenwich Biosciences, Inc., Carlsbad, CA and Royston Gray, PhD, Pharmacology Scientist, GW Research Ltd, London, United Kingdom - SXM05
Systematic Review of Real-World Evidence on the Effect of Nabiximols on Pain and Sleep Impairment in Persons with MS (PwMS) Experiencing Spasticity
Mary A. Willis, MD1, Kate Nichol, PhD2 and Kelly Hollenack, PharmD2, (1)Department of Neurology, University of Mississippi Medical Center, Jackson, MS, (2)Greenwich Biosciences, Inc., Carlsbad, CA - SXM06
Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence
Thomas P. Leist, MD1, Michele Cole, PharmD, MS2, Hoa Le, PhD3, Sumit Verma, BPharm, MS4 and Alex Keenan, MS2, (1)Comprehensive Multiple Sclerosis Center, Division of Clinical Neuroimmunology, Jefferson University, Philadelphia, PA, (2)Research and Development, Janssen Pharmaceuticals, Titusville, NJ, (3)Janssen Scientific Affairs, Janssen Pharmaceuticals, Titusville, NJ, (4)Health Economics and Outcomes Research, StatInMed, Plano, TX - SXM07
Is a Light Hand on the Wheels Enough? Postural Sway in Standing with Different Methods of Walker Use in Multiple Sclerosis and Controls
Najala Orrell, MD1, Pawan Kumar, PhD Student2, Alison Oates, PhD2, Joel Lanovaz, PhD2, Michael Levin, FRCPC3, Aman Saini, MD3 and Katherine Knox, FRCPC1, (1)Department of Physical Medicine and Rehabilitation, University of Saskatchewan, Saskatoon, SK, Canada, (2)College of Kinesiology, University of Saskatchewan, Saskatoon, SK, Canada, (3)Office of the Saskatchewan Multiple Sclerosis Clinical Research Chair, University of Saskatchewan, Saskatoon, SK, Canada - SXM08
Sources of Cannabis Information and Medical Guidance Among People with Multiple Sclerosis: Narcoms Survey Results
Robert J. Fox, MD1, Amber Salter, PhD2, Gary Cutter, PhD3, Joshua R. Steinerman, MD4, Kate Nichol, PhD4 and Karry Smith, PhD, MPH4, (1)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (2)Washington University School in St. Louis, St Louis, MO, (3)The University of Alabama at Birmingham, Birmingham, AL, (4)Greenwich Biosciences, Inc., Carlsbad, CA - SXM09
Arbaclofen Extended-Release for Spasticity in Multiple Sclerosis: Responder Analysis of a Phase 3 Randomized, Placebo-Controlled Clinical Study OS440-3004
Samuel F Hunter, MD, PhD, Advanced Neurosciences Institute, Franklin, TN, Daniel Kantor, MD, FAAN, FANA, Florida Atlantic University, Boca Raton, FL, James L Rogers, PhD, Summit Analytical LLC, Denver, CO, Tina deVries, PhD, Osmotica Pharmaceuticals, Bridgewater, NJ and Darin T Okuda, MD, UT Southwestern Medical Center, Dallas, TX - SXM10
Symptom Burden and Treatment Goals of People with MS Spasticity: Results from SEEN-MSS, a Large-Scale, Self-Reported Survey
Scott D. Newsome, DO, MSCS, FAAN, FANA1, Ben Thrower, MD2, Barry Hendin, MD3, Joanne Wagner, PT, PhD4, Sherry Danese, PhD5 and Jenifer Patterson, ARNP, MSCN4, (1)Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, (2)Andrew C. Carlos MS Institute, Shepherd Center, Atlanta, GA, (3)Neurology, University of Arizona, Tucson, AZ, (4)Greenwich Biosciences, Carlsbad, CA, (5)Outcomes Insights, Agoura Hills, CA - SXM11
Implementation of a Depression Screening Tool (PHQ-9) for Adult Multiple Sclerosis Patients at an Outpatient Neurology Clinic.
Selina Yeasmin, CRNP, Outpatient Neurology Department, UMMC, Baltimore, MD and Lori Edwards, DrPH, BSN, RN